

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/01974 A2

- (51) International Patent Classification⁷: A61K 31/00 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US00/18260
- (22) International Filing Date: 30 June 2000 (30.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/345,782 1 July 1999 (01.07.1999) US
- (71) Applicant: GUILFORD PHARMACEUTICALS INC.
[US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).
- (72) Inventor: SLUSHER, Barbara, S.; 7424 Longfield Drive, Kingsville, MD 21087 (US).
- (74) Agent: NATH, Gary, M.; Nath & Associates PLLC, 6th floor, 1030 15th Street, N.W., Washington, DC 20005-1503 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/01974 A2

(54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING ANXIETY, ANXIETY DISORDERS AND MEMORY IMPAIRMENT USING NAALADASE INHIBITORS

(57) Abstract: The present invention relates to pharmaceutical compositions and methods of using NAALADase inhibitors for treating glutamate-mediated diseases, disorders and conditions selected from the group consisting of anxiety, anxiety disorders and memory impairment.

WO 01/01974

PCT/US00/18260

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING
ANXIETY, ANXIETY DISORDERS AND MEMORY IMPAIRMENT
USING NAALADASE INHIBITORS

5

BACKGROUND OF THE INVENTION

The present invention relates to pharmaceutical compositions and methods for treating glutamate-mediated diseases, disorders and conditions, particularly anxiety, anxiety disorders and memory impairment, using NAALADase inhibitors.

Anxiety disorders afflict over 23 million Americans. These people are tormented by panic attacks, obsessive thoughts, flashbacks, nightmares or countless frightening physical symptoms. Classes of drugs which are prescribed for the treatment of anxiety disorders include the benzodiazepines (such as diazepam) and buspirone hydrochloride. Although the benzodiazepines have achieved widespread acceptance since their introduction in the 1960's, their use is restricted due to their adverse side effects, in particular their tendency to induce dependence. While lacking the dependence-inducing side effects of the benzodiazepines, buspirone hydrochloride has a slow onset of action (about 4 weeks). Thus, there is a need for new pharmaceutical compositions and methods for treating anxiety and anxiety disorders.

Excessive activation of glutamate receptors has been implicated in anxiety and anxiety disorders. Significantly higher glutamate plasma levels have been

30

WO 01/01974

PCT/US00/18260

2

detected in patients with mood disorders than in comparison subjects. In social interaction tests on rats, the blocking of basal glutamate excitation elicited anxiolytic-like effects.

5 It is widely published that glutamate modulators possess anxiolytic properties. In animal models of anxiolytic activity, NMDA antagonists reduced separation-induced ultrasonic vocalizations in rat pups, antagonized the suppressive effects of
10 punishment on locomotor activity in the four-plate test on mice, enhanced exploration in the open arms of an elevated plus maze by rats, and blocked anxiety responses elicited by GABAA receptor blockade in the basolateral amygdala of rats; AMPA/kainate antagonists
15 increased the percentage of entries of rats into the open arms of an elevated plus maze, and caused a dose-dependent increase of punished drinking behavior in a conflict-suppressed drinking test on rats; AMPA antagonists normalized pathologically increased
20 electromyogram (EMG) activity in the hind limb extensor muscles of rats; mGluR antagonists produced a dose-dependent anticonflict effect in a conflict drinking Vogel test on rats; and mGluR agonists exhibited anxiolytic effects on mice in the fear
25 potentiated startle and elevated plus maze models.

 Studies also suggest that the pharmacological effect of anxiolytic agents is mediated through the glutamatergic system. In an intact neuronal circuit

WO 01/01974

PCT/US00/18260

3

of a model extrahypothalamic CNS area, systemic injection and local application of progesterone suppressed glutamate excitation. Microdialysis shows that anxiogenic beta-carboline significantly increases glutamate efflux in the prefrontal cortex of rats. Reports also indicate that the anxiolytic effects of riluzole are mediated by the blockade of glutamate transmission. Concordantly, the inhibition of glutamate synthesis has been proposed as a possible mechanism for the anxiolytic activity of gabapentin.

Excessive activation of glutamate receptors has also been implicated in neurodegenerative disorders (e.g., Alzheimer's disease, Huntington's disease and AIDS encephalopathy) and in the generation of long-term potentiation, which is regarded as an electrophysiological manifestation of learning and memory. Specifically, the NMDA subtype of glutamate receptor appears to be involved in learning processes because the NMDA antagonist 2-amino-5-phosphonopentanoate (AP5) selectively impairs learning and blocks long-term potentiation in rats. It has thus been proposed that deterioration in glutamatergic systems might account for impairment in cognitive function observed in aged animals or in Alzheimer's disease.

Recent studies have implicated NAALADase in the pathogenesis of glutamate-mediated disorders. Lesion studies on rat and neuropathological studies on post-

WO 01/01974

PCT/US00/18260

4

mortem tissue from patients with amyotrophic lateral sclerosis (ALS) indicate large decreases of N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) tissue concentrations occurring in association with neuronal degeneration, and increases of NAA and NAAG in cerebral spinal fluid (CSF) from patients with ALS. Concordantly, abnormal NAAG levels and NAALADase activity have also been observed in post-mortem prefrontal and limbic brain tissue of schizophrenic patients.

Autopsy studies also suggest a strong correlation between NAAG/NAA and Alzheimer's disease. In post-mortem brain tissue, NAA and NAAG levels were found to be selectively decreased in brain areas (hippocampus and amygdala) affected by Alzheimer's disease pathology.

Although not limited to any one particular theory, it is believed that NAALADase inhibitors block glutamate release pre-synaptically. The inventors have discovered that the glutamate blocking activity of NAALADase inhibitors has direct therapeutic applications for the pharmacotherapy of glutamate-mediated diseases, disorders and conditions, including without limitation anxiety, anxiety disorders and neurodegenerative diseases. Since neurodegenerative diseases are one of the leading causes of memory impairment, the inventors theorize that NAALADase inhibitors may be also beneficial in the treatment of

WO 01/01974

PCT/US00/18260

5

memory impairment.

Most research and development activity to date have focused on blocking post-synaptic glutamate receptors with compounds such as NMDA antagonists, glycine antagonists, and other post-synaptic excitatory amino acid (EAA) receptor blockers. Unfortunately, these agents produce severe toxicities even under normal conditions, thus limiting their clinical use.

By contrast, NAALADase inhibitors inhibit glutamate release presynaptically without interacting with post-synaptic glutamate receptors. Since NAALADase inhibitors do not appear to alter basal glutamate levels, they may be devoid of the behavioral toxicities associated with post-synaptic glutamate antagonists.

Until a few years ago, only a few NAALADase inhibitors had been identified and they were used in non-clinical research. Examples of these compounds include general metallopeptidase inhibitors such as o-phenanthroline, metal chelators such as EGTA and EDTA, and peptide analogs such as quisqualic acid and β -NAAG. These compounds either have toxic side effects or are incapable of being administered in pharmaceutically effective amounts. In view of the broad range of potential applications, there is a need for new NAALADase inhibitors and pharmaceutical compositions and methods of using the same.

WO 01/01974

PCT/US00/18260

6

SUMMARY OF THE INVENTION

The present invention relates to a method for treating a glutamate mediated disease, disorder or condition selected from the group consisting of anxiety, anxiety disorder and memory impairment, comprising administering an effective amount of a NAALADase inhibitor to a mammal in need of such treatment.

The present invention also relates to a pharmaceutical composition comprising:

- (i) an effective amount of a NAALADase inhibitor for treating a glutamate mediated disease, disorder or condition selected from the group consisting of anxiety, anxiety disorder and memory impairment; and
- (ii) a pharmaceutically acceptable carrier.

DETAILED DESCRIPTION OF THE INVENTION**Definitions**

"Compound 1" refers to pure and impure forms of 2-(2-sulfanylethyl)pentanedioic acid, or the compound prepared by Example 23.

"Compound 2" refers to 2-[[[(2,3,4,5,6-pentafluorobenzyl)hydroxyphosphinyl)methyl]-pentanedioic acid.

"Compound 3" refers to 2-(phosphonomethyl)-pentanedioic acid (PMPA).

"Effective amount" refers to the amount required

WO 01/01974

PCT/US00/18260

7

to produce the desired effect. "Therapeutically effective amount" refers to the amount required to treat anxiety, anxiety disorders and memory impairment.

5 "Isosteres" refer to elements, molecules or ions having similar or identical physical properties. Typically, two isosteric molecules have similar or identical volumes and shapes. Ideally, isosteric compounds should be isomorphic and able to co-crystallize. Among the other physical properties that
10 isosteric compounds usually share are boiling point, density, viscosity and thermal conductivity. However, certain properties are usually different: dipolar moments, polarity, polarization, size and shape since
15 the external orbitals may be hybridized differently. The term "isosteres" encompass "bioisosteres".

"Carboxylic acid isosteres" include without limitation direct derivatives such as hydroxamic acids, acyl-cyanamide and acylsulfonamides; planar
20 acidic heterocycles such as tetrazoles, mercaptoazoles, sulfinylazoles, sulfonylazoles, isoxazoles, isothiazoles, hydroxythiadiazole and hydroxychromes; and nonplanar sulfur- or phosphorus-derived acidic functions such as phosphinates,
25 phosphonates, phosphonamides, sulphonates, sulphonamides, and acylsulphonamides. *The Practice of Medicinal Chemistry*, Academic Press, 1996.

"Metabolite" refers to a substance produced by

WO 01/01974

PCT/US00/18260

8

metabolism or by a metabolic process.

"Pharmaceutically acceptable equivalent" includes without limitation pharmaceutically acceptable salts, hydrates, metabolites, prodrugs and carboxylic isosteres. Many pharmaceutically acceptable equivalents are expected to have similar or the same *in vitro* or *in vivo* activity as the compounds of formulas I-VI.

"Pharmaceutically acceptable salt" refers to a salt of the inventive compounds which possesses the desired pharmacological activity and which is neither biologically nor otherwise undesirable. The salt can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate heptanoate, hexanoate, hydrochloride hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalene-sulfonate, nicotinate, oxalate, thiocyanate, tosylate and undecanoate. Examples of a base salt include without limitation ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as

WO 01/01974

PCT/US00/18260

9

arginine and lysine. Also, the basic nitrogen-containing groups can be quarternized with agents including: lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides such as benzyl and phenethyl bromides.

10 "Pharmaceutically acceptable prodrug" refers to a derivative of the inventive compounds which undergoes biotransformation prior to exhibiting its pharmacological effect(s). The prodrug is formulated with the objective(s) of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity). The prodrug can be readily prepared from the inventive compounds using methods known in the art, such as those described by *Burger's Medicinal Chemistry and Drug Chemistry*, Fifth Ed., Vol. 1, pp. 172-178, 949-982 (1995), or methods readily apparent to one skilled in the art. For example, the inventive compounds can be transformed into prodrugs by converting one or more of the hydroxy or carboxy groups into esters.

"Alkyl" refers to a branched or unbranched

WO 01/01974

PCT/US00/18260

10

saturated hydrocarbon chain comprising a designated number of carbon atoms. For example, a C₁-C₆ straight or branched alkyl hydrocarbon chain contains 1 to 6 carbon atoms, and includes but is not limited to substituents such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl, and the like, unless otherwise indicated.

"Alkenyl" refers to a branched or unbranched unsaturated hydrocarbon chain comprising a designated number of carbon atoms. For example, a C₂-C₆ straight or branched alkenyl hydrocarbon chain contains 2 to 6 carbon atoms having at least one double bond, and includes but is not limited to substituents such as ethenyl, propenyl, iso-propenyl, butenyl, iso-butenyl, tert-butenyl, n-pentenyl, n-hexenyl, and the like, unless otherwise indicated.

"Alkoxy" refers to the group -OR wherein R is alkyl as herein defined. Preferably, R is a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms.

"Halo" or "halogen" refers to fluoro, chloro, bromo and iodo, unless otherwise indicated.

"Isomers" refer to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the arrangement or configuration of the atoms.

"Stereoisomers" refer to compounds which have identical chemical constitution, but differ as regards

WO 01/01974

PCT/US00/18260

11

to the arrangement of the atoms or groups in space.

"Optical isomers" refer to either of two kinds of stereoisomers. One kind is represented by mirror-image structures called enantiomers, which result from the presence of one or more asymmetric carbon atoms in the compound (glyceraldehyde, lactic acid, sugars, tartaric acid, amino acids). The other kind is exemplified by diastereoisomers, which are not mirror images. These occur in compounds having two or more asymmetric carbon atoms; thus, such compounds have 2^n optical isomers, where n is the number of asymmetric carbon atoms.

"Enantiomers" refer to stereoisomers which are non-superimposable mirror images of one another.

"Enantiomer-enriched" refers to a mixture in which one enantiomer predominates.

"Racemic" refers to a mixture containing equal parts of individual enantiomers.

"Non-racemic" refers to a mixture containing unequal parts of individual enantiomers.

"Animal" refers to a living organism having sensation and the power of voluntary movement and requirement for its existence oxygen and organic food. Examples include without limitation a mammal such as a member of the human, equine, porcine, bovine, murine, canine or feline species. In the case of a human, the term "animal" may also be referred to as a "patient".

WO 01/01974

PCT/US00/18260

12

"Disease" refers to any deviation from or interruption of the normal structure or function of any part, organ, or system (or combination thereof) of the body that is manifested by a characteristic set of symptoms and signs and whose etiology, pathology, and prognosis may be known or unknown. Dorland's Illustrated Medical Dictionary, W.B. Saunders Co., 27th ed. (1988).

"Disorder" refers to any derangement or abnormality of function; a morbid physical or mental state. Dorland's Illustrated Medical Dictionary, W.B. Saunders Co., 27th ed. (1988).

"Anxiety" includes without limitation the unpleasant emotion state consisting of psychophysiological responses to anticipation of unreal or imagined danger, ostensibly resulting from unrecognized intrapsychic conflict. Physiological concomitants include increased heart rate, altered respiration rate, sweating, trembling, weakness, and fatigue; psychological concomitants include feelings of impending danger, powerlessness, apprehension, and tension. Dorland's Illustrated Medical Dictionary, W.B. Saunders Co., 27th ed. (1988).

"Anxiety Disorder" includes without limitation mental disorders in which anxiety and avoidance behavior predominate. Dorland's Illustrated Medical Dictionary, W.B. Saunders Co., 27th ed. (1988). Examples include without limitation panic attack,

WO 01/01974

PCT/US00/18260

13

agoraphobia, panic disorder, acute stress disorder, chronic stress disorder, specific phobia, simple phobia, social phobia, substance induced anxiety disorder, organic anxiety disorder, obsessive compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, and anxiety disorder NOS. Other anxiety disorders are characterized in Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association 4th ed. 1994). The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for pathologic psychological conditions and that these systems evolve with medical scientific progress.

"Memory impairment" refers to a diminished mental registration, retention or recall of past experiences, knowledge, ideas, sensations, thoughts or impressions. Memory impairment may affect short and long-term information retention, facility with spatial relationships, memory (rehearsal) strategies, and verbal retrieval and production. Common causes of memory impairment are age, severe head trauma, brain anoxia or ischemia, alcoholic-nutritional diseases, drug intoxications and neurodegenerative diseases. For example, memory impairment is a common feature of neurodegenerative diseases such as Alzheimer's disease and senile dementia of the Alzheimer type. Memory impairment also occurs with other kinds of dementia

WO 01/01974

PCT/US00/18260

14

such as multi-infarct dementia, a senile dementia caused by cerebrovascular deficiency, and the Lewy-body variant of Alzheimer's disease with or without association with Parkinson's disease. Creutzfeldt-Jakob disease is a rare dementia with which memory impairment is associated. It is a spongiform encephalopathy caused by the prion protein; it may be transmitted from other sufferers or may arise from gene mutations. Loss of memory is also a common feature of brain-damaged patients. Brain damage may occur, for example, after a classical stroke or as a result of an anaesthetic accident, head trauma, hypoglycemia, carbon monoxide poisoning, lithium intoxication, vitamin (B₁, thiamine and B₁₂) deficiency, or excessive alcohol use. Korsakoff's amnesic psychosis is a rare disorder characterized by profound memory loss and confabulation, whereby the patient invents stories to conceal his or her memory loss. It is frequently associated with excessive alcohol intake. Memory impairment may furthermore be age-associated; the ability to recall information such as names, places and words seems to decrease with increasing age. Transient memory loss may also occur in patients, suffering from a major depressive disorder, after electro-convulsive therapy.

"Mental disorder" refers to any clinically significant behavioral or psychological syndrome characterized by the presence of distressing symptoms

WO 01/01974

PCT/US00/18260

15

or significant impairment of functioning. Mental disorders are assumed to result from some psychological or organic dysfunction of the individual; the concept does not include disturbances that are essentially conflicts between the individual and society (social deviance).

"Treating" refers to:

(i) preventing a disease, disorder or condition from occurring in an animal which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it;

(ii) inhibiting the disease, disorder or condition, i.e., arresting its development; and/or

(iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

In relation to memory impairment, "treating" refers to:

(i) preventing memory impairment from occurring in an animal which may be predisposed to memory impairment but has not yet been diagnosed as having it;

(ii) inhibiting memory impairment, i.e., arresting its development;

(iii) relieving memory impairment, i.e., causing its regression; and/or

(iv) enhancing memory.

"Enhancing memory performance" refers to

WO 01/01974

PCT/US00/18260

16


improving or increasing the mental faculty by which to register, retain or recall past experiences, knowledge, ideas, sensations, thoughts or impressions.

"NAAG" refers to N-acetyl-aspartyl-glutamate, an important peptide component of the brain, with levels comparable to the major inhibitor neurotransmitter gamma-aminobutyric acid (GABA). NAAG is neuron-specific, present in synaptic vesicles and released upon neuronal stimulation in several systems presumed to be glutamatergic. Studies suggest that NAAG may function as a neurotransmitter and/or neuromodulator in the central nervous system, or as a precursor of the neurotransmitter glutamate.

"NAALADase" refers to N-acetylated α -linked acidic dipeptidase, a membrane-bound metallopeptidase which catabolizes NAAG to N-acetylaspartate ("NAA") and glutamate ("GLU"):

Catabolism of NAAG by NAALADase

20



25

Based upon amino acid sequence homology, NAALADase has been assigned to the M28 peptidase family. NAALADase

WO 01/01974

PCT/US00/18260

17

is also called prostate specific membrane antigen (PSM) or human glutamate carboxypeptidase II (GCP II), EC number 3.4.17.21. It is believed that NAALADase is a co-catalytic zinc/zinc metallopeptidase. NAALADase shows a high affinity for NAAG with a Km of 540 nM. If NAAG is a bioactive peptide, then NAALADase may serve to inactivate NAAG's synaptic action. Alternatively, if NAAG functions as a precursor for glutamate, the primary function of NAALADase may be to regulate synaptic glutamate availability.

"NAALADase inhibitor" refers to any compound which inhibits NAALADase enzyme activity.

"Inhibition", in the context of enzymes, refers to reversible enzyme inhibition such as competitive, uncompetitive and non-competitive inhibition. Competitive, uncompetitive and non-competitive inhibition can be distinguished by the effects of an inhibitor on the reaction kinetics of an enzyme. Competitive inhibition occurs when the inhibitor combines reversibly with the enzyme in such a way that it competes with a normal substrate for binding at the active site. The affinity between the inhibitor and the enzyme may be measured by the inhibitor constant, K_i , which is defined as:

$$K_i = \frac{[E][I]}{[EI]}$$

WO 01/01974

PCT/US00/18260

18

wherein [E] is the concentration of the enzyme, [I] is the concentration of the inhibitor, and [EI] is the concentration of the enzyme-inhibitor complex formed by the reaction of the enzyme with the inhibitor.

5 Unless otherwise specified, K_i as used herein refers to the affinity between the inventive compounds and NAALADase. " IC_{50} " is a related term used to define the concentration or amount of a compound which is required to cause a 50% inhibition of the target
10 enzyme.

"Acid containing metal chelator" refers to any compound having (i) a functional group capable of interacting with the metal(s) at the active site of the NAALADase enzyme; and (ii) an acid portion which
15 interacts at the recognition site of the NAALADase enzyme.

METHODS OF USE

The present invention relates to a method for
20 treating a glutamate mediated disease, disorder or condition selected from the group consisting of anxiety, anxiety disorder and memory impairment, comprising administering an effective amount of a NAALADase inhibitor to a mammal in need of such
25 treatment.

Anxiety disorders treatable by the inventive methods include without limitation mental disorders in which anxiety and avoidance behavior predominate, such

WO 01/01974

PCT/US00/18260

19

as panic attack, agoraphobia, panic disorder, acute stress disorder, specific phobia, simple phobia, social phobia, substance induced anxiety disorder, organic anxiety disorder, obsessive compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, and anxiety disorder NOS.

Memory impairments treatable by the inventive methods include without limitation diminished mental registration, retention or recall of past experiences, knowledge, ideas, sensations, thoughts or impressions.

PHARMACEUTICAL COMPOSITIONS

The present invention further relates to a pharmaceutical composition comprising:

- (i) an effective amount of a NAALADase inhibitor for treating a glutamate mediated disease, disorder or condition selected from the group consisting of anxiety, anxiety disorder and memory impairment; and
- (ii) a pharmaceutically acceptable carrier.

The pharmaceutical composition may further comprise at least one additional therapeutic agent.

PREFERRED NAALADASE INHIBITORS

Although not limited to any one particular theory, it is believed that the NAALADase inhibitors used in the inventive methods and pharmaceutical compositions modulate levels of glutamate by acting on


WO 01/01974

PCT/US00/18260

20

a storage form of glutamate which is hypothesized to be upstream from the effects mediated by the NMDA receptor.

A preferred NAALADase inhibitor is a compound of
5 formula I:



10

or a pharmaceutically acceptable equivalent, wherein:

Y is CR₃R₄, NR₅ or O;

R₁ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, Ar, COOR, NR₆R₇ and OR, wherein said
15 alkyl, alkenyl, cycloalkyl and cycloalkenyl are unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, phenoxy, benzyloxy, COOR, NR₆R₇ and Ar;

20

R₂ is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, Ar, halo and carboxy, wherein said
25 alkyl, alkenyl, cycloalkyl and cycloalkenyl are unsubstituted or substituted with one or more substituent(s) independently selected from the group

WO 01/01974

PCT/US00/18260

21

consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, phenoxy, benzyloxy, NR₆R₇ and Ar;

5 R₃ and R₄ are independently hydrogen or C₁-C₃ alkyl;

 R₅ is hydrogen or C₁-C₃ alkyl;

 R, R₆ and R₇ are independently selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl and Ar, wherein said alkyl, alkenyl, cycloalkyl and cycloalkenyl are unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, phenoxy, benzyloxy and Ar; and

 Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 4-indolyl, 2-furyl, 3-furyl, tetrahydrofuranyl, tetrahydropyranyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, wherein said Ar is unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, phenoxy, benzyloxy, carboxy and NR₁R₂.

 Preferably, Y is CH₂.

WO 01/01974

PCT/US00/18260

22

More preferably, when Y is CH₂, then R₂ is - (CH₂)₂COOH.

Most preferably, when Y is CH₂ and R₂ is - (CH₂)₂COOH, then R₁ is hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, benzyl, phenyl or OR, wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, benzyl and phenyl are unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, phenoxy, benzyloxy, NR₆R₇, benzyl and phenyl.

Preferred compounds of formula I are selected from the group consisting of:

2-(phosphonomethyl)pentanedioic acid;

2-[[(2-carboxyethyl)hydroxyphosphinyl]methyl]pentanedioic acid;

2-[(benzylhydroxyphosphinyl)methyl]pentanedioic acid;

2-[(phenylhydroxyphosphinyl)methyl]pentanedioic acid;

2-[[((hydroxy)phenylmethyl)hydroxyphosphinyl]methyl]pentanedioic acid;

2-[(butylhydroxyphosphinyl)methyl]pentanedioic acid;

2-[[(3-methylbenzyl)hydroxyphosphinyl]methyl]pentanedioic acid;

WO 01/01974

PCT/US00/18260

23

2-[(3-phenylpropylhydroxyphosphinyl)methyl]-
pentanedioic acid;

2-[[(4-fluorophenyl)hydroxyphosphinyl]methyl]-
pentanedioic acid;

5 2-[(methylhydroxyphosphinyl)methyl]pentanedioic
acid;

2-[(phenylethylhydroxyphosphinyl)methyl]-
pentanedioic acid;

10 2-[[(4-methylbenzyl)hydroxyphosphinyl]methyl]-
pentanedioic acid;

2-[[(4-fluorobenzyl)hydroxyphosphinyl]methyl]-
pentanedioic acid;

2-[[(4-methoxybenzyl)hydroxyphosphinyl]methyl]-
pentanedioic acid;

15 2-[[(3-trifluoromethylbenzyl)hydroxyphosphinyl]-
methyl]pentanedioic acid;

2-[[(4-trifluoromethylbenzyl)hydroxyphosphinyl]-
methyl]pentanedioic acid;

20 2-[[(2-fluorobenzyl)hydroxyphosphinyl]methyl]-
pentanedioic acid;

2-[[(2,3,4,5,6-pentafluorobenzyl)hydroxy-
phosphinyl]methyl]pentanedioic acid; and

pharmaceutically acceptable equivalents.

25 More preferably, the compound of formula I is 2-
[[(2,3,4,5,6-pentafluorobenzyl)hydroxyphosphinyl]-
methyl]pentanedioic acid or a pharmaceutically
acceptable equivalent. Most preferably, the compound
of formula I is an enantiomer or an enantiomer-

WO 01/01974

PCT/US00/18260

24

enriched mixture.

Representative compounds of formula I wherein R₁ is substituted with COOR include without limitation:

2 - [[2-carboxypropyl)hydroxyphosphinyl)methyl] -
5 pentanedioic acid;

2 - [[2-carboxybutyl)hydroxyphosphinyl)methyl] -
pentanedioic acid;

2 - [[[2-carboxypentyl)hydroxyphosphinyl)methyl] -
pentanedioic acid;

10 2 - [[[2-carboxy-3-phenylpropyl)hydroxyphosphinyl] -
methyl]pentanedioic acid;

2 - [[2-carboxy-3-naphthylpropyl)hydroxy-
phosphinyl)methyl]pentanedioic acid;

15 2 - [[2-carboxy-3-pyridylpropyl)hydroxyphosphinyl] -
methyl]pentanedioic acid;

2 - [[2-benzyloxycarbonyl)-3-phenylpropyl)hydroxy-
phosphinyl)methyl]pentanedioic acid;

2 - [[2-methoxycarbonyl)-3-phenylpropyl)hydroxy-
phosphinyl)methyl]pentanedioic acid;

20 2 - [[[3-carboxy-2-methoxycarbonyl)propyl)hydroxy-
phosphinyl)methyl]pentanedioic acid;

2 - [[[4-carboxy-2-methoxycarbonyl)butyl)hydroxy-
phosphinyl)methyl]pentanedioic acid; and

pharmaceutically acceptable equivalents.

25 Representative compounds of formula I wherein R₁ is substituted with NR₆R, include without limitation:

2 - [{[benzylamino]benzyl}(hydroxyphosphinyl)) -
methyl]pentanedioic acid;

WO 01/01974

PCT/US00/18260

25

2-[({[carboxyamino]benzyl} (hydroxyphosphinyl)) -
methyl]pentanedioic acid;

2-[({[benzylamino]methyl} (hydroxyphosphinyl)) -
methyl]pentanedioic acid;

5 2-[({[acetylamino]methyl} (hydroxyphosphinyl)) -
methyl]pentanedioic acid;

2-[({[diphenylamino]methyl} (hydroxyphosphinyl)) -
methyl]pentanedioic acid;

10 2-[({[phenylamino]methyl} (hydroxyphosphinyl)) -
methyl]pentanedioic acid;

2-([([phenylcarboxamido]methyl} (hydroxy-
phosphinyl))methyl]pentanedioic acid;

2-([([phenylsulfonamido]methyl} (hydroxy-
phosphinyl))methyl]pentanedioic acid;

15 2-[(([(4-fluorophenyl) amino]methyl} (hydroxy-
phosphinyl))methyl]pentanedioic acid;

2-[(([(4-methoxyphenyl) amino]methyl} (hydroxy-
phosphinyl))methyl]pentanedioic acid;

20 2-[(([(4-methylphenyl) amino]methyl} -
(hydroxyphosphinyl))methyl]pentanedioic acid;

2-[(([(4-tert-butylphenyl) amino]methyl} -
(hydroxyphosphinyl))methyl]pentanedioic acid;

2-[(([(thioformanilido) amino]benzyl} -
(hydroxyphosphinyl))methyl]pentanedioic acid;

25 2-[(([[1,3-dioxo-2,3-dihydro-1H-2-isoindolyl]-
methyl}hydroxyphosphinyl)methyl]pentanedioic acid; and

pharmaceutically acceptable equivalents.


Another preferred NAALADase inhibitor is a

WO 01/01974

PCT/US00/18260

26

compound of formula II




5


or a pharmaceutically acceptable equivalent, wherein:

X is a moiety of formula III, IV or V

10




III



IV

15



V;

20

m and n are independently 0, 1, 2, 3 or 4;

Z is SR_{13} , SO_3R_{13} , SO_2R_{13} , SOR_{13} , $\text{SO}(\text{NR}_{13})\text{R}_{14}$ or $\text{S}(\text{NR}_{13}\text{R}_{14})_2\text{R}_{15}$;

B is N or CR_{16} ;

25

A is O, S, $\text{CR}_{17}\text{R}_{18}$ or $(\text{CR}_{17}\text{R}_{18})_m\text{S}$; R_9 and R_{13} are hydrogen; R_8 , R_{10} , R_{11} , R_{12} , R_{14} , R_{15} , R_{16} , R_{17} and R_{18} are

WO 01/01974

PCT/US00/18260

27

independently hydrogen, C₁-C₈ straight or branched chain alkyl, C₂-C₈ straight or branched chain alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, Ar₁, hydroxy, carboxy, carbonyl, amino, amido, cyano, isocyano, nitro, sulfonyl, sulfoxy, thio, thiocarbonyl, thiocyano, formanilido, thioformamido, sulfhydryl, halo, haloalkyl, trifluoromethyl or oxy, wherein said alkyl, alkenyl, cycloalkyl and cycloalkenyl are independently unsubstituted or substituted with one or more substituent(s); and

Ar₁ is a carbocyclic or heterocyclic moiety, which is unsubstituted or substituted with one or more substituent(s);

provided that when X is a moiety of formula III and A is O, then n is 2, 3 or 4; when X is a moiety of formula III and A is S, then n is 2, 3 or 4; and when X is a moiety of formula III and A is (CR₁₇R₁₈)_mS, then n is 0, 2, 3 or 4.

Possible substituents of said alkenyl, cycloalkyl, cycloalkenyl, and Ar₁ include without limitation C₁-C₈ alkyl, C₂-C₈ chain alkenyl, C₁-C₈ alkoxy, C₂-C₈ alkenyloxy, phenoxy, benzyloxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, hydroxy, carboxy, carbonyl, amino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, thiocyano, formanilido, thioformamido, sulfhydryl, halo, haloalkyl, trifluoromethyl, and carbocyclic and

WO 01/01974

PCT/US00/18260

28

heterocyclic moieties. Carbocyclic moieties include alicyclic and aromatic structures.

Examples of useful carbocyclic and heterocyclic moieties include without limitation phenyl, benzyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinolizinyl, furyl, thiophenyl, imidazolyl, oxazolyl, benzoxazolyl, thiazolyl, isoxazolyl, isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, trithianyl, indolizinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl.

Representative compounds of formula II wherein X is a moiety of formula IV, R_8 is $-(CH_2)_2COOH$, R_9 is hydrogen, and B is CR_{16} , include without limitation:

2-(dithiocarboxymethyl)pentanedioic acid;
2-(1-dithiocarboxyethyl)pentanedioic acid; and
pharmaceutically acceptable equivalents.

Representative compounds of formula II wherein X is a moiety of formula IV, R_8 is $-(CH_2)_2COOH$, R_9 is

WO 01/01974

PCT/US00/18260

29

hydrogen, and B is N, include without limitation:

2-dithiocarboxyaminopentanedioic acid;

2-[(N-methyldithiocarboxy)amino]pentanedioic acid; and

5 pharmaceutically acceptable equivalents.

Representative compounds of formula II wherein X is a moiety of formula V include without limitation:

2-benzyl-4-sulfanylpentanoic acid;

2-benzyl-4-sulfanylpentanoic acid;

10 2-(3-pyridylmethyl)-4-sulfanylpentanoic acid;

2-(3-pyridylmethyl)-4-sulfanylpentanoic acid;

2-benzyl-3-sulfanylpentanoic acid;


2-benzyl-3-sulfanylpentanoic acid;

2-(4-pyridylmethyl)-3-sulfanylpentanoic acid; and

15 pharmaceutically acceptable equivalents.

In a preferred embodiment of formula II, the NAALADase inhibitor is a compound of formula VI

20



VI

or a pharmaceutically acceptable equivalent, wherein:

25 n is 0, 1, 2 or 3;

Z is SH, SO₃R₁₃, SO₂R₁₃, SOR₁₃ or S(NR₁₃R₁₄)₂R₁₅; and

A is O, S or CR₁₇R₁₈.

Preferably, Z is SH.

WO 01/01974

PCT/US00/18260

30

More preferably, when Z is SH, then R₈ is -
(CH₂)₂COOH.

Preferred compounds of formula VI are selected
from the group consisting of:

- 5 2-(2-sulfanylethyl)pentanedioic acid;
 3-(2-sulfanylethyl)-1,3,5-pentanetricarboxylic
acid;
 2-(2-sulfanylpropyl)pentanedioic acid;
 2-(2-sulfanylbutyl)pentanedioic acid;
10 2-(2-sulfanyl-2-phenylethyl)pentanedioic acid;
 2-(2-sulfanylhhexyl)pentanedioic acid;
 2-(2-sulfanyl-1-methylethyl)pentanedioic acid;
 2-[1-(sulfanylmethyl)propyl]pentanedioic acid;
 2-(3-sulfanylpentyl)pentanedioic acid;
15 2-(3-sulfanylpropyl)pentanedioic acid;
 2-(3-sulfanyl-2-methylpropyl)pentanedioic acid;
 2-(3-sulfanyl-2-phenylpropyl)pentanedioic acid;
 2-(3-sulfanylbutyl)pentanedioic acid;
 2-[3-sulfanyl-2-(phenylmethyl)propyl]pentanedioic
20 acid;
 2-[2-(sulfanylmethyl)butyl]pentanedioic acid;
 2-[2-(sulfanylmethyl)pentyl]pentanedioic acid;
 2-(3-sulfanyl-4-methylpentyl)pentanedioic acid;
and
25 pharmaceutically acceptable equivalents.

More preferably, the compound of formula VI is
selected from the group consisting of 2-(2-
sulfanylethyl)pentanedioic acid, 2-(2-sulfanylpropyl)-

WO 01/01974

PCT/US00/18260

31

pentanedioic acid, 2-(3-sulfanylpropyl)pentanedioic acid and pharmaceutically acceptable equivalents. Most preferably, the compound of formula VI is an enantiomer or an enantiomer-enriched mixture.

5 Other NAALADase inhibitors are described in U.S. Patents Nos. 5,672,592, 5,795,877, 5,863,536 and 5,880,112, and allowed U.S. Patent Applications Nos. 08/825,997, 08/833,628, 08/835,572 and 08/842,360 for which the issue fees have been paid, the entire
10 contents of which patents and applications are herein incorporated by reference.

 The compounds used in the methods and pharmaceutical compositions of the present invention possess one or more asymmetric carbon center(s) and
15 are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures of optical isomers. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes well
20 known in the art, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then
25 separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the

WO 01/01974

PCT/US00/18260

32

use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules, for example, esters, amides, acetals, ketals, and the like, by reacting compounds used in the inventive methods and pharmaceutical compositions with an optically active acid in an activated form, an optically active diol or an optically active isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. In some cases hydrolysis to the parent optically active drug is not necessary prior to dosing the patient since the compound can behave as a prodrug. The optically active compounds used in the inventive methods and pharmaceutical compositions can likewise be obtained by utilizing optically active starting materials.

It is understood that the compounds used in the inventive methods and pharmaceutical compositions encompass optical isomers as well as racemic and non-racemic mixtures.

25

SYNTHESIS OF NAALADASE INHIBITORS

Some of the NAALADase inhibitors used in the inventive methods and pharmaceutical compositions can be readily prepared by standard techniques of organic


WO 01/01974

PCT/US00/18260

33

chemistry, utilizing the general synthetic pathways depicted in U.S. Patents Nos. 5,672,592, 5,795,877, 5,863,536 and 5,880,112, and allowed U.S. Patent Applications Nos. 08/825,997, 08/833,628, 08/835,572 and 08/842,360 for which the issue fees have been paid, the entire contents of which patents and applications are herein incorporated by reference.

NAALADase inhibitors of formula I can be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathways depicted below in Schemes I-IX. Precursor compounds can be prepared by methods known in the art, such as those described by Jackson et al., *J. Med. Chem.*, Vol. 39, No. 2, pp. 619-622 (1996) and Froestl et al., *J. Med. Chem.*, Vol. 38, pp. 3313-3331 (1995).

Scheme I

Methods of substituting the R groups are known in the

WO 01/01974

PCT/US00/18260

34


art. Additional methods of synthesizing phosphinic acid esters are described in *J. Med. Chem.*, Vol. 31, pp. 204-212 (1988), and set forth below in Scheme II:

5


WO 01/01974

PCT/US00/18260


35

Scheme II**Method A**

10



- | | | | | |
|----|---------------------------|--------------------------------|-----------------------------------|---|
| A. | $R_1 = (CH_2)_3\text{Ph}$ | H. | $R_1 = n\text{-C}_7\text{H}_{15}$ | |
| 15 | B. | $(CH_2)_4\text{Ph}$ | I. | $n\text{-C}_8\text{H}_{17}$ |
| | C. | $(CH_2)_5\text{Ph}$ | J. | $n\text{-C}_9\text{H}_{19}$ |
| | D. | $(CH_2)_4(\text{P-F-Ph})$ | K. | $\text{CH}_2\text{CHCH}_3\text{C}_4\text{H}_9$ |
| | E. | $(CH_2)_4\text{- (3-pyridyl)}$ | L. | $\text{CH}_2(\text{CH}_3)\text{C}(\text{CH}_3)_2$ |
| | F. | $n\text{-C}_5\text{H}_{11}$ | | |
| 20 | G. | $n\text{-C}_6\text{H}_{13}$ | | |

Method BN. $R_1 = n\text{-C}_4\text{H}_9$

WO 01/01974

PCT/US00/18260

36


O. $\text{CHCH}_3\text{C}_5\text{H}_{11}$

Starting with the aforementioned phosphinic acid esters, there are a variety of routes for preparing the compounds of formula I. For example, a general route has been described in *J. Med. Chem.*, Vol. 39, pp. 619-622 (1996), and is set forth below in Scheme III.


10

Scheme III

15



20



25

Other routes for preparing the compounds of formula I are set forth below in Scheme IV and Scheme V. Scheme IV and Scheme V show the starting material as a phosphinic acid derivative and the R group as any reasonable chemical substituent including without limitation the substituents listed in Scheme II and

WO 01/01974


PCT/US00/18260

37


throughout the specification.

Scheme IV

5




10




15

Scheme V

20



25



Another route for preparing the compounds of formula I allows for aromatic substitution at R₁, and

WO 01/01974

PCT/US00/18260


38

is set forth below in Scheme VI.


5

Scheme VI


10



15



20




Another route for preparing the compounds of formula I allows for aromatic substitution at the R_2 position, and is set forth below in Scheme VII.

WO 01/01974

PCT/US00/18260

39

Scheme VII


Another route for preparing the compounds of formula I wherein Y is NR_5 is set forth below in Scheme

WO 01/01974

PCT/US00/18260

40

VIII.



Scheme VIII

Another route for preparing the compounds of formula I wherein Y is oxygen is set forth below in Scheme IX.

WO 01/01974

PCT/US00/18260

41

Scheme IX

The compounds of formula I wherein R₁ is substituted with COOR can be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathways depicted below in Scheme X. Precursor compounds can be prepared by methods known in the art, such as those described by Jackson et al., *J. Med. Chem.*, Vol. 39, No. 2, pp. 619-622 (1996) and Froestl et al., *J. Med. Chem.*, Vol. 38, pp. 3313-3331 (1995).

PCT/US00/18260




Scheme X




WO 01/01974

PCT/US00/18260

43




20



WO 01/01974

PCT/US00/18260


44



10 The compounds of formula I wherein R₁ is substituted with NR₆R, can be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathways depicted below in Schemes XI and XII. Precursor compounds can be prepared by methods known in the art.

15


Scheme XI



WO 01/01974

PCT/US00/18260

45



Scheme XII

The NAALADase inhibitors of formula II wherein X is a moiety of formula III, and A is O or $\text{CR}_{17}\text{R}_{18}$, can be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathways depicted below in Schemes XIII-XXII. Precursor compounds can be prepared by methods known in the art.

WO 01/01974

PCT/US00/18260

46

Scheme XIIIScheme XIV


WO 01/01974

PCT/US00/18260

47


Scheme XV

5




1. BuLi, THF, -78


10



15




20



WO 01/01974

PCT/US00/18260






48

Scheme XVI

WO 01/01974

PCT/US00/18260

49


Scheme XVII

WO 01/01974


PCT/US00/18260

50

Scheme XVIII




10



WO 01/01974

PCT/US00/18260

51

Scheme XIX


WO 01/01974

PCT/US00/18260

52


Scheme XX

5



10


15



Scheme XXI

20


25



WO 01/01974

PCT/US00/18260

53

Scheme XXII

The NAALADase inhibitors of formula II wherein X is a moiety of formula III and A is $(CR_{17}R_{18})_mS$ can be readily prepared via standard synthetic methods such as oxidation of the corresponding thiol.

The compounds of formula II wherein X is a moiety of formula III and A is S can be readily prepared via standard synthetic techniques. For example, Scheme XXII can be modified by starting with an appropriately substituted thio compound. In addition, compounds of this class can also be prepared by Michael addition of an appropriately substituted thiol derivative to an α -, β -unsaturated ester.

The compounds of formula II wherein X is a moiety

PCT/US00/18260

of formula IV can be readily prepared using standard synthetic pathways, such as reacting a glutamate derivative with carbon disulfide.

5

15

25

The NAALADase inhibitors may also be administered in the form of sterile injectable preparations, for

WO 01/01974

PCT/US00/18260

55

example, as sterile injectable aqueous or oleaginous suspensions. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as solvents or suspending mediums. For this purpose, any bland fixed oil such as a synthetic mono- or di-glyceride may be employed. Fatty acids such as oleic acid and its glyceride derivatives, including olive oil and castor oil, especially in their polyoxyethylated forms, are useful in the preparation of injectables. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.

Additionally, the NAALADase inhibitors may be administered orally in the form of capsules, tablets, aqueous suspensions or solutions. Tablets may contain carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate. Capsules may contain diluents including lactose and dried corn starch. Aqueous suspensions may contain emulsifying and suspending agents combined with the

WO 01/01974

PCT/US00/18260

56

active ingredient. The oral dosage forms may further contain sweetening and/or flavoring and/or coloring agents.

5 The NAALADase inhibitors may further be administered rectally in the form of suppositories. These compositions can be prepared by mixing the drug with suitable non-irritating excipients which are solid at room temperature, but liquid at rectal temperature such that they will melt in the rectum to
10 release the drug. Such excipients include cocoa butter, beeswax and polyethylene glycols.

Moreover, the NAALADase inhibitors may be administered topically, especially when the conditions addressed for treatment involve areas or organs
15 readily accessible by topical application, including neurological disorders of the eye, the skin or the lower intestinal tract.

For topical application to the eye, or ophthalmic use, the compounds can be formulated as micronized
20 suspensions in isotonic, pH adjusted sterile saline or, preferably, as a solution in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, the compounds may be formulated into ointments, such as
25 petrolatum.

For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in,

WO 01/01974

PCT/US00/18260

57

for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.

5 Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester
10 wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

Topical application to the lower intestinal tract can be effected in rectal suppository formulations (see above) or in suitable enema formulations.

15 The NAALADase inhibitors used in the methods of the present invention may be administered by a single dose, multiple discrete doses or continuous infusion. Since the compounds are small, easily diffusible and relatively stable, they are well suited to continuous
20 infusion. Pump means, particularly subcutaneous pump means, are preferred for continuous infusion.

DOSAGE

Dose levels on the order of about 0.1 mg to about
25 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels being about 0.1 mg to about 1,000 mg. The specific dose level for any particular patient

WO 01/01974

PCT/US00/18260

58

will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; 5 the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, *in vitro* dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models 10 are also helpful. The considerations for determining the proper dose levels are well known in the art.

In a preferred embodiment, the NAALADase inhibitors are administered in lyophilized form. In this case, 1 to 100 mg of a NAALADase inhibitor may be 15 lyophilized in individual vials, together with a carrier and a buffer, such as mannitol and sodium phosphate. The compound may be reconstituted in the vials with bacteriostatic water before administration.

The NAALADase inhibitors used in the inventive 20 methods may be administered in combination with one or more therapeutic agents. Specific dose levels for these agents will depend upon considerations such as those identified above.

25

ADMINISTRATION REGIMEN

For the methods of the present invention, any administration regimen regulating the timing and sequence of drug delivery can be used and repeated as

WO 01/01974

PCT/US00/18260

59

necessary to effect treatment. Such regimen may include pretreatment and/or co-administration with additional therapeutic agents.

5 **COMBINATION WITH OTHER TREATMENTS**

In the inventive methods, the NAALADase inhibitors can be co-administered with one or more additional therapeutic agent(s), preferably other anxiolytic agents, memory enhancing agents or agents
10 capable of treating the underlying cause of memory impairment.

Examples of anxiolytic agents which may be combined with the NAALADase inhibitors include without limitation benzodiazepines (chlordiazepoxide,
15 diazepam, clorazepate, flurazepam, halazepam, prazepam, clonazepam, quazepam, alprazolam, lorazepam, oxazepam, temazepam, triazolam); barbiturates; β blockers; and buspirone.

The NAALADase inhibitors can be co-administered
20 with one or more therapeutic agents either (i) together in a single formulation, or (ii) separately in individual formulations designed for optimal release rates of their respective active agent. Each formulation may contain from about 0.01% to about
25 99.99% by weight, preferably from about 3.5% to about 60% by weight, of a NAALADase inhibitor, as well as one or more pharmaceutical excipients, such as wetting, emulsifying and pH buffering agents.

WO 01/01974

PCT/US00/18260

60

In Vivo Toxicity of NAALADase Inhibitors

The *in vivo* toxicological effect of NAALADase inhibition has been examined in mice. The results show that NAALADase inhibitors are non-toxic to mice, suggesting that it would be similarly non-toxic to humans when administered at therapeutically effective amounts. Representative disclosure may be found in U.S. Patents Nos. 5,672,592, 5,795,877, 5,863,536 and 5,880,112, and allowed U.S. Patent Applications Nos. 08/825,997, 08/833,628, 08/835,572 and 08/842,360, for which the issue fees have been paid, the entire contents of which patents and applications are herein incorporated by reference.

15 In Vitro Inhibition of NAALADase Activity

Various compounds used in the inventive methods and pharmaceutical compositions have been tested for *in vitro* inhibition of NAALADase activity. Some of the results are set forth in U.S. Patents Nos. 5,672,592, 5,795,877, 5,863,536 and 5,880,112, and allowed U.S. Patent Applications Nos. 08/825,997, 08/833,628, 08/835,572 and 08/842,360, the entire contents of which patents and applications are herein incorporated by reference.




25 Other results are provided below:

WO 01/01974

PCT/US00/18260

61

IN VITRO INHIBITION OF NAALADASE ACTIVITY


		Compound	K _i (nM)
5			0.3
10		2-(phosphonomethyl)pentanedioic acid	
			700
15		2-(phosphonomethyl)succinic acid	
			2
20		2-[[[(2-carboxyethyl)hydroxyphosphinyl]-methyl]pentanedioic acid	

WO 01/01974


PCT/US00/18260

62

5




53




36

10




54

15




114

20




180

25



148




232

WO 01/01974

PCT/US00/18260


63



WO 01/01974

PCT/US00/18260

64




WO 01/01974

PCT/US00/18260


65

5




2

10




548

15




234

20



740

25




198

WO 01/01974

PCT/US00/18260


66

5



4250


10



13


15

20



0.6

25




95

WO 01/01974

PCT/US00/18260


67

5




2

10




313

15



2000

20



52


25

WO 01/01974

PCT/US00/18260


68

5



118


10



175


15

20



34

25







6

WO 01/01974

PCT/US00/18260




69




WO 01/01974

PCT/US00/18260

70



20




2-(2-sulfanylethyl)pentanedioic acid

WO 01/01974

PCT/US00/18260

71


5



4750

2-(2-sulfanylhexyl)pentanedioic acid

10




843

15

2-(1-methyl-2-sulfanylethyl)pentanedioic acid

20



158


2-(2-sulfanylpropyl)pentanedioic acid

25

WO 01/01974


PCT/US00/18260

72




2-(2-phenyl-2-sulfanylethyl)pentanedioic acid

10



2-(1-ethyl-2-sulfanylethyl)pentanedioic acid

20




2-(2-naphthyl-2-sulfanylethyl)pentanedioic acid


WO 01/01974

PCT/US00/18260


73



2-(3-sulfanylpropyl)pentanedioic acid



2-(3-sulfanyl-2-methylpropyl)pentanedioic acid




2-(4-sulfanylbtyl)pentanedioic acid

WO 01/01974

PCT/US00/18260

74



2-[2-[(3,5-dicarboxypentyl)dithio]ethyl]pentanedioic
acid

10

EXAMPLES

The following examples are illustrative of the
15 present invention and are not intended to be
limitations thereon. Unless otherwise indicated, all
percentages are based upon 100% by weight of the final
composition.

20

EXAMPLE 1

Preparation of 2-[[2,3,4,5,6-pentafluorobenzyl)- hydroxyphosphinyl]methyl]pentanedioic acid

Scheme V: $R_1 = 2,3,4,5,6$ -pentafluorobenzyl

Hexamethyldisilazane (21.1 mL, 100 mmol) was added to
25 vigorously stirred ammonium phosphinate (8.30 g, 100
mmol), and the resulting suspension was stirred at
105° C for 2 hours. A solution of 2,3,4,5,6-
pentafluorobenzyl bromide (5.0 g, 27.0 mmol) was then
added dropwise to the suspension at 0° C. The mixture

WO 01/01974

PCT/US00/18260

75

was stirred at room temperature for 19 hours. The reaction mixture was then diluted with dichloromethane (50 mL) and washed with 1 N HCl (50 mL). The organic layer was separated, dried over Na₂SO₄, and concentrated to give 4.72 g of a white solid. This was dissolved in dichloromethane (50 mL) and benzyl alcohol (3.24 g, 30 mmol) was added to the solution. 1,3-dicyclohexyl-carbodiimide (DCC) (6.19 g, 30 mmol) was then added to the solution at 0° C, and the suspension was stirred at room temperature for 14 hours. The solvent was removed under reduced pressure and the residue was suspended in EtOAc. The resulting suspension was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography (hexanes: EtOAc, 4:1 to 1:1) to give 2-[[[(2,3,4,5,6-pentafluorobenzyl)-hydroxyphosphinyl]-methyl]pentanedioic acid as a white solid (34% yield). R_f 0.69 (*i*-PrOH: H₂O, 7:3).

¹H NMR (D₂O): δ 1.8-2.0 (m, 3H), 2.1-2.3 (m, 1H), 2.3-2.5 (m, 2H), 2.7-2.9 (m, 1H), 3.29 (d, 2H).

Elemental Analysis

Calculated C₁₃H₁₂F₅O₆P, 0.45 H₂O: C, 39.20; H, 3.26.

Found: C, 39.17; H, 3.28.

25

EXAMPLE 2

Preparation of 2-(Phosphonomethyl)pentanedioic Acid

Scheme III

WO 01/01974

PCT/US00/18260

76

Dibenzyl 2-methylenepentanedioate

Benzyl acrylate (500 g, 3.0 mol) was heated in an oil bath to 100° C. Heating was stopped and HMPT (10 g, 61 mmol) was added dropwise while maintaining an internal temperature below 140° C. Once addition was complete, the mixture was stirred and cooled to room temperature. A slurry of silica (5:1 Hexane/EtOAc) was added and the mixture was placed in a column containing a plug of dry silica. The column was washed with 1:1 Hexane/EtOAc and the fractions were combined and evaporated to give 450 g of clear light golden liquid. The liquid was distilled under high vacuum (200 μ Hg) at 185° C to give 212 g (42%) of a clear and colorless liquid.

¹H NMR (CDCl₃): 7.3 ppm (m, 10H), 6.2 ppm (s, 1H), 5.6 ppm (s, 1H), 5.2 ppm (s, 2H), 5.1 ppm (s, 2H), 2.6 ppm (m, 4H).

Dibenzyl 2-[[bis(benzyloxy)phosphoryl]methyl]-pentanedioate

Dibenzyl phosphite (9.5 g, 36 mmol) in 350 ml of dichloromethane was cooled to 0° C. To this stirring solution was added trimethyl aluminum (18.2 ml, 2.0 M solution in hexane, 36.4 mmol). After 30 minutes, dibenzyl 2-methylenepentanedioate (2, 6.0 g, 37 mmol) in 90 ml of dichloromethane was added dropwise over 10 minutes. The clear and colorless solution was then warmed to room temperature and left to stir overnight.

WO 01/01974

PCT/US00/18260

77

The mixture was then quenched by the slow addition of 5% HCl. After stirring an additional 1.5 hours the lower organic layer was removed and the aqueous layer extracted once with 100 ml of dichloromethane. The organics were combined, dried (MgSO_4), and evaporated to give a clear light golden liquid. The liquid was chromatographed on silica gel (4cm*30cm) and eluted with a gradient (4:1-1:1) solvent system (Hexane/EtOAc). The fractions containing the desired product were combined and evaporated to yield dibenzyl 2-[[bis(benzyloxy)phosphoryl]methyl]pentanedioate (7.1 g, 42%) as a clear and colorless liquid. The liquid was then distilled on a Kughleror apparatus at 0.5 mm Hg and 195-200° C. The distillate was discarded and the remaining light golden oil was chromatographed on silica gel (1:1, Hexane/EtOAc) to give 2.9 g of dibenzyl 2-[[bis(benzyloxy)phosphoryl]methyl]pentanedioate as a clear and colorless oil. TLC R_f 0.5 (1:1 Hexane/EtOAc).

¹H NMR (CDCl_3): 7.1-7.4 (m, 20H), 5.05 (s, 2H), 4.8-5.03 (m, 6H), 2.8 (1H), 2.22-2.40 (m, 3H), 1.80-2.02 (m, 3H).

2-(Phosphonomethyl)pentanedioic Acid

The benzyl pentanedioate (2.9 g, 4.9 mmol) was added to a mixture of 20 ml of methanol containing 0.29 g (6 mol%) of 10% Pd/C. This mixture was hydrogenated on a Parr hydrogenator at 40 psi for 24

WO 01/01974

PCT/US00/18260

78

hours, filtered and evaporated to give a clear slightly golden viscous oil (3, 1.0 g, 90%).

^1H -NMR (D_2O): 2.6-2.78 (m, 1H), 2.25-2.40 (m, 2H), 1.75-2.15 (m, 4H).

5

EXAMPLE 3

Preparation of 2-[[[2-(carboxy)propyl]hydroxy-phosphinyl]methyl]pentanedioic acid

Scheme X

10

Di-tert-butyl 2-methylenepentanedioate

Tert-butyl acrylate (465 g, 3.628 mol) was warmed to 100° C under nitrogen, then hexamethylphosphorous triamide (10 g, 61.2 mmol) was added dropwise and the addition rate was adjusted to maintain the reaction temperature at 100° C. The reaction mixture was allowed to cool, then poured over a plug of silica (~1000 ml) and washed completely off the silica with 4:1 hexane/ethyl acetate. The solvent was removed under reduced pressure and the resulting oil was distilled. Some material was collected from room temperature to 50° C under high vacuum, and discarded. The temperature was then raised to ~80° C and the product (300 g, 65 %, b.p. 67-70° C at 300 μ) was collected as a clear oil. ^1H NMR (CDCl_3): δ 1.4 (m, 18H), 2.4 (t, 2H), 2.6 (t, 2H), 5.5 (s, 1H), 6.0 (s, 1H).

25

WO 01/01974

PCT/US00/18260

79

**Di-tert-butyl 2-[(hydroxyphosphinyl)methyl]-
pentanedioate**

A mixture of ammonium phosphinate (162.6 g, 1.96 mol) and 1,1,1,3,3,3-hexamethyldisilazane (316 g, 1.96 mol) was heated to 105° C for 2 hours. The reaction mixture was cooled in an ice bath and di-tert-butyl 2-methylenepentane-1,5-dioate (251 g, 0.979 mol) dissolved in dichloromethane (1000 ml) was added dropwise. The reaction mixture was allowed to warm to room temperature overnight. The reaction mixture was then quenched with distilled water (500 ml) and the organic layer was retained. The aqueous layer was washed a second time with dichloromethane and the combined organic layers were dried over magnesium sulfate. Then the solvent was removed under reduced pressure leaving a slightly yellow oil (315 g, 100 %). This product was found to be of sufficient purity for use in the next reaction. ¹H NMR (CDCl₃): δ 1.4 (m, 18H), 1.9 (m, 3H), 2.1 (m, 1H), 2.3 (m, 2H), 2.7 (m, 1H), 6.5 & 7.9 (d, 1H, the P-H), 11.0 (s, 1H).

**Di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]-
pentanedioate**

To a solution of di-tert-butyl 2-[(hydroxyphosphinyl)methyl]pentane-1,5-dioate (315 g, 0.977 mol) in dichloromethane (1000 ml) cooled in an ice bath and under nitrogen were added tert-butanol (123.1 g, 1.66 mol), 4-dimethylaminopyridine (1 g, 8.2 mmol),

WO 01/01974

PCT/US00/18260

80

and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (281 g, 1.47 mol). The reaction was allowed to stir overnight. Water was added to the reaction mixture and the dichloromethane layer was retained and dried, and the solvent was removed under reduced pressure. The resulting residue was purified by column chromatography and the desired product was eluted with 1:1 to 2:3 hexane/ethyl acetate. The fractions containing product were concentrated under reduced pressure leaving a clear oil (260 g, 70 %). ¹H NMR (CDCl₃): δ 1.4 (m, 27H), 1.8 (m, 1H), 1.9 (m, 2H), 2.1 (m, 1H), 2.3 (m, 2H), 2.7-2.8 (m, 1H), 6.7 & 8.0 (d, 1H, the P-H).

Di-tert-butyl 2-[[[2-(benzylcarboxy)propyl]tert-butoxyphosphinyl)methyl]pentanedioate

To a solution of di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]pentane-1,5-dioate (13.62 g, 36.0 mmol) and benzyl methacrylate (6.35 g, 36.0 mmol) in THF (100 ml) under nitrogen was added sodium hydride (0.14 g, 60 % dispersion in oil, 3.60 mmol). After three hours, the reaction mixture was poured into water (300 ml) and ether (100 ml) was added. The organic layer was separated and retained, and the aqueous layer was washed again with ether (100 ml). The combined organic extracts were dried over magnesium sulfate and the solvent was removed under reduced pressure. The resulting residue was purified

WO 01/01974

PCT/US00/18260

81

by column chromatography and the product was eluted with 2:3 EtOAc/Hexane. The solvent was removed under reduced pressure leaving a clear oil (10.5 g, 53 %). ¹H NMR (CDCl₃): δ 1.3 (m, 3H), 1.5 (m, 27H), 1.7 (m, 2H), 1.9 (m, 2H), 2.2 (m, 4H), 2.6 (m, 1H), 2.9 (m, 1H), 5.1 (m, 2H), 7.3 (m, 5H).

2-[[[2-(Benzylcarboxy)propyl]hydroxyphosphinyl]-methyl]pentanedioic acid

To a solution of di-tert-butyl 2-[[[2-(benzylcarboxy)propyl]tert-butoxyphosphinyl]methyl]pentane-1,5-dioate (1.6 g, 2.89 mmol) in dichloromethane (10 ml) under nitrogen was added trifluoroacetic acid (10 ml). The reaction mixture was stirred for two hours and then concentrated under reduced pressure. Additional dichloromethane was added to the reaction residue and removed under reduced pressure. The product was dissolved in ethyl acetate and washed with water, then the organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure leaving a clear oil (800 mg, 72 %). ¹H NMR (D₂O): δ 1.2 (m, 3H), 1.6-1.8 (m, 4H), 2.1 (m, 2H), 2.2 (m, 2H), 2.6 (m, 1H), 2.8 (m, 1H), 5.0 (m, 2H), 7.3 (m, 5H). Analysis calculated for C₁₇H₂₃PO₈ · 1.0 H₂O: C, 50.50; H, 6.23. Found: C, 50.52; H, 5.92.

Di-tert-butyl 2-[[[2-(carboxy)propyl]tert-butoxy-

WO 01/01974

PCT/US00/18260

82

phosphinyl)methyl]pentanedioate

A solution of di-tert-butyl 2-[[[2-(benzyl-carboxy)propyl]tert-butoxyphosphinyl)methyl]pentane-1,5-dioate (8.9 g, 16.1 mmol), palladium on carbon catalyst (10 %, 1.0 g) and ethyl acetate (100 ml) was shaken under hydrogen (60 psi) for 16 hours. The reaction mixture was filtered over celite and the filtrate was concentrated under reduced pressure leaving a clear oil (7.5 g, 100 %). ¹H NMR (CDCl₃):

5 δ 1.3 (d, 3H), 1.4-1.5 (m, 27H), 1.8 (m, 2H), 1.9 (m, 2H), 2.2 (m, 4H), 2.7 (m, 1H), 2.9 (m, 1H).

10

2-[[[2-(Carboxy)propyl]hydroxyphosphinyl)methyl]-pentanedioic acid

15 To a solution of di-tert-butyl 2-[[[2-(carboxy)-propyl]tert-butoxyphosphinyl)methyl]pentane-1,5-dioate (2.1 g, 4.53 mmol) in dichloromethane (10 ml) under nitrogen was added trifluoroacetic acid (10 ml). The reaction mixture was stirred for two hours and then

20 concentrated under reduced pressure. Additional dichloromethane was added to the reaction residue and removed under reduced pressure. The resulting residue was triturated with acetonitrile, then dried under reduced pressure leaving a thick clear oil (1.2 g, 89

25 %). ¹H NMR (D₂O): δ 1.2 (d, 3H), 1.9 (m, 4H), 2.2 (m, 2H), 2.4 (m, 2H), 2.8 (m, 2H). Analysis calculated for C₁₀H₁₇PO₈ 0.2 CH₃CN: C, 41.03; H, 5.83. Found: C, 41.05; H, 5.92.

WO 01/01974

PCT/US00/18260

83

EXAMPLE 4

Preparation of 2-[[{[Benzylamino]methyl}(hydroxy-
phosphinyl))methyl]pentanedioic acid

Scheme XI

5

Di-tert-butyl 2-[[((tert-butoxy){[benzylamino]methyl}-
phosphoryl)methyl]pentane-1,5-dioate

A solution of 1,3,5-tribenzylhexahydro-1,3,5-
triazine (14.30 g, 40.0 mmol) and di-tert-butyl 2-
10 {[(tert-butoxy)phosphoryl)methyl]pentane-1,5-dioate
(37.85 g, 100 mmol) in toluene (200 mL) was stirred at
110 °C for 14 hours. The solvent was removed under
reduced pressure and the residual yellow oil was
purified by silica gel chromatography (hexanes/ethyl
15 acetate, 2/1) to give 23.40 g of light yellow oil (43%
yield): ¹H NMR (CDCl₃) δ 1.40-1.48 (m, 27H), 1.7-2.1
(m, 4H), 2.2-2.4 (m, 3H), 2.6-3.0 (m, 3H), 3.8-4.0 (m,
2H), 7.2-7.4 (m, 5H).

20 2-[[{[Benzylamino]methyl}(hydroxyphosphinyl))methyl]-
pentanedioic acid

To a solution of di-tert-butyl 2-[[((tert-butoxy)-
{[benzylamino]methyl}phosphoryl)methyl]pentane-1,5-
dioate (0.498 g, 1.0 mmol) in dichloromethane (10 mL)
25 was added trifluoroacetic acid (5 mL) at 0° C, and the
mixture was stirred at room temperature for eighteen
hours. The solvent was removed under reduced
pressure. The residual oil was taken up with

WO 01/01974

PCT/US00/18260

84

dichloromethane (10 mL) and concentrated. This process was repeated three times to remove trifluoroacetic acid completely. The resulting oil was crystallized from methanol to give 0.174 g of
5 white solid (53% yield): ^1H NMR (D_2O) δ 1.40-1.48 (m, 27H), 1.7-2.1 (m, 4H), 2.2-2.4 (m, 3H), 2.6-3.0 (m, 3H), 3.8-4.0 (m, 2H), 7.2-7.4 (m, 5H).

WO 01/01974

PCT/US00/18260

85

EXAMPLE 5

Preparation of 2-[({[phenylamino]methyl}(hydroxy-
phosphinyl))methyl]pentanedioic acid

Using a method similar to that described above in
5 Example 4, 2-[({[phenylamino]methyl}(hydroxy-
phosphinyl))methyl]pentanedioic acid was synthesized:
¹H NMR (D₂O) δ 1.4-1.6 (m, 1H), 1.7-1.9 (m, 3H), 2.2-
2.4 (m, 2H), 2.2-2.4 (m, 2H), 2.5-2.7 (m, 1H), 3.53
(d, J = 8.8 Hz, 2H), 7.3-7.5 (m, 5H).

10

EXAMPLE 6

Preparation of 2-[({[4-fluorophenylamino]methyl}-
(hydroxyphosphinyl))methyl]pentanedioic acid

Using a method similar to that described above in
15 Example 4, 2-[({[4-fluorophenylamine]methyl}(hydroxy-
phosphinyl))methyl]pentanedioic acid was synthesized:
¹H NMR (D₂O) δ 1.5-1.7 (m, 1H), 1.8-2.0 (m, 3H), 2.3-
2.5 (m, 2H), 2.6-2.7 (m, 1H), 3.84 (d, J = 9.0 Hz,
2H), 7.2-7.5 (4H).

20

EXAMPLE 7

Preparation of 2-[({[4-methoxyphenylamino]methyl}-
(hydroxyphosphinyl))methyl]pentanedioic acid

Using a method similar to that described above in
25 Example 4, 2-[({[4-Methoxyphenylamino]methyl}-
(hydroxyphosphinyl))methyl]pentanedioic acid was
synthesized: ¹H NMR (D₂O) δ 1.2-1.3 (m, 1H), 1.6-1.7
(m, 3H), 2.22-2.23 (m, 2H), 2.3-2.5 (m, 1H), 3.4 (d,

WO 01/01974

PCT/US00/18260

86

$J = 8.9 \text{ Hz, } 2\text{H}), 3.7 \text{ (s, } 3\text{H}), 7.0 \text{ (d, } J = 12 \text{ Hz, } 2\text{H}), 7.4 \text{ (d, } J = 12 \text{ Hz, } 2\text{H}).$

EXAMPLE 8

5 Preparation of 2-([(phenylsulfonamido)methyl]-
 (hydroxyphosphinyl)methyl)pentanedioic acid

Using a method similar to that described above in Example 4, 2-([(phenylsulfonamido)methyl](hydroxyphosphinyl)methyl)pentanedioic acid was synthesized:

10 $^1\text{H NMR (D}_2\text{O)} \delta 1.6\text{--}2.1 \text{ (m, } 4\text{H}), 2.3\text{--}2.4 \text{ (m, } 2\text{H}), 2.5\text{--}2.7 \text{ (m, } 1\text{H}), 2.9\text{--}3.1 \text{ (m, } 2\text{H}), 7.7\text{--}8.0 \text{ (m, } 5\text{H}).$

EXAMPLE 9

15 Preparation of 2-([(phenylcarboxamido)methyl]-
 (hydroxyphosphinyl)methyl)pentanedioic acid

Scheme XII

Di-tert-butyl 2-([(aminomethyl)(tert-butoxy)-
phosphoryl)methyl]pentane-1,5-dioate

20 To a solution of di-tert-butyl 2-([(tert-butoxy)-
 { [benzylamino]methyl}phosphoryl)methyl]pentane-1,5-
 dioate (8.20 g, 16.5 mmol) in ethanol (100 mL) was
 added palladium on carbon (0.50 g), and the suspension
 was shaken under hydrogen (50 psi) for 4 days. The
25 catalyst was removed by filtration through a pad of
 Celite. The filtrate was concentrated to give 6.629
 g of colorless oil (99% yield): $^1\text{H NMR (CD}_3\text{OD)} \delta 1.40\text{--}1.60 \text{ (m, } 27\text{H}), 1.80\text{--}2.00 \text{ (m, } 3\text{H}), 2.2\text{--}2.4 \text{ (m, } 3\text{H}),$

WO 01/01974

PCT/US00/18260

87

2.7-3.0 (m, 3H).

Di-tert-butyl 2-(({tert-butoxy}[(phenylcarboxamido)-methyl]phosphoryl)methyl)pentane-1,5-dioate

5 To a solution of di-tert-butyl 2-([(aminomethyl)-(tert-butoxy)phosphoryl)methyl]pentane-1,5-dioate (1.222 g, 3.0 mmol) and benzoyl chloride (0.46 mL, 4.0 mmol) in dichloromethane (10 mL) was added triethylamine (0.56 mL, 4.0 mmol) at 0° C, and the
10 mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with dichloromethane (15 mL), washed with 1 N HCl (25 mL), dried over Na₂SO₄, and concentrated. The crude material was
15 purified by silica gel chromatography (ethyl acetate/hexanes = 2/1) to give 1.259 g of colorless oil (74% yield): ¹H NMR (CDCl₃) δ 1.30-1.60 (m, 27H), 1.60-2.00 (m, 3H), 2.20-2.40 (m, 3H), 2.70-2.90 (m, 3H), 3.5-4.2 (m, 2H), 7.0-7.3 (m, 1H), 7.4-7.6 (m, 3H), 7.8-7.9 (m, 1H).

20

2-([(Phenylcarboxamido)methyl](hydroxyphosphinyl))-methyl)pentanedioic acid

 To a solution of di-tert-butyl 2-(({tert-butoxy}-[(phenylcarboxamido)methyl]phosphoryl)methyl)pentane-
25 1,5-dioate (1.230 g, 2.4 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (5 mL) at room temperature, and the mixture was stirred at room temperature for 18 hours. The solvent was removed

WO 01/01974

PCT/US00/18260

88

under reduced pressure. The residual oil was taken up with dichloromethane (10 mL) and concentrated. This process was repeated three times to remove trifluoroacetic acid completely. The resulting oil was crystallized from acetonitrile-water to give 0.620 g of white solid (75% yield): ^1H NMR (D_2O) δ 1.9-2.1 (m, 3H), 2.2-2.4 (m, 1H), 2.4-2.6 (m, 2H), 2.8-3.0 (m, 1H), 3.7-3.9 (m, 2H), 7.5-7.9 (m, 5H).


10

EXAMPLE 10

Preparation of 2-(2-sulfanylethyl)pentanedioic acidScheme XIII, R_{10} = hydrogen

3-(2-Oxotetrahydro-3-thiophenyl)propanoate

15



20


To a cooled solution (-78°C) of lithium diisopropylamide (LDA) (98 mmol) in THF (100 ml) was added dropwise γ -thiobutyrolactone (10 g, 98 mmol). After stirring for fifteen minutes, ethyl 3-bromopropanoate (35.4 g, 196 mmol) was added and the reaction allowed to warm to room temperature overnight. The solvent was removed under reduced

WO 01/01974

PCT/US00/18260

89

pressure and the resulting residue was purified by column chromatography yielding 3 g (16 %) of clear oil. ^1H NMR (CDCl_3) δ 1.2 (t, 3H), 1.7 (m, 1H), 1.9 (m, 1H), 2.1 (m, 1H), 2.4 (t, 2H), 2.5 (m, 2H), 3.3 (t, 2H), 4.2 (q, 2H).

2-(2-sulfanylethyl)pentanedioic acid

To a solution of ethyl 3-(2-oxotetrahydro-3-thiophenyl)propanoate (0.77 g, 3.81 mmol) in THF (5 ml) was added sodium hydroxide (1 M in water, 5 ml). The mixture was allowed to stir for two days, then the THF was removed under reduced pressure, the aqueous layer was washed with ether, then acidified to pH 1 with HCl and extracted with ethyl acetate. The combined ethyl acetate extracts were dried over magnesium sulfate and the solvent was removed under reduced pressure. The resulting residue was purified by column chromatography yielding a 150 mg of clear oil (20 %). ^1H NMR ($\text{d}_6\text{-DMSO}$) δ 1.7 (m, 3H), 1.8 (m, 1H), 2.2 (m, 2H), 2.3-2.5 (m, 4H). Analysis calculated for $\text{C}_7\text{H}_{12}\text{SO}_4$: C, 43.74; H, 6.29; S, 16.68.

WO 01/01974

PCT/US00/18260

90

Found: C, 43.61; H, 6.39; S, 16.55.

EXAMPLE 11

Preparation of 2-(3-sulfanylpropyl)pentanedioic acid

5 Scheme XIX

2,2-dimethyl-5-[3-[(triphenylmethyl)thio]propyl]-1,3-dioxane-4,6-dione (I)

20 mmol of 3-[(triphenylmethyl)thio]propionic
10 acid (6.9 g) was dissolved with 22 mmol Meldrum's acid
(2,2-dimethyl-1,3-dioxane-4,6-dione) (3.2 g) and 31
mmol 4-dimethylaminopyridine (3.85 g) in 100 ml CH₂Cl₂.
The reaction mixture was cooled to -5° C and a
solution of 22 mmol of dicyclohexyl carbodiimide (4.74
15 g) in 50 ml CH₂Cl₂ was added dropwise over 1 hour. The
mixture was left at < 0° C temperature overnight,
during which time tiny crystals of dicyclohexylurea
precipitated. After filtration, the reaction mixture
was washed 4x with 10% KHSO₄, 1x with brine and dried
20 with MgSO₄ for 2 hours. This solution was used for the
second step without characterization or further
purification.

The solution from the previous reaction was
cooled to -5°C and 13.3 ml (220 mmol) of 98% acetic
25 acid was added. Then 1.85 g (50 mmol) of NaBH₄ was
added in small portions while stirring over 1 hour.
The reaction mixture was left in the refrigerator
overnight and then washed 3x with water and 2x with

WO 01/01974

PCT/US00/18260

91

brine. Organic phase was dried with MgSO_4 , filtered and evaporated to dryness. The residue was dissolved in EtOAc, the precipitated small amount of dicyclohexylurea was filtered off and filtrate was brought to crystallization by addition of hexane. Yield 7.5 g of 2,2-dimethyl-5-[3-[(triphenylmethyl)-thio]propyl]-1,3-dioxane-4,6-dione (I) (86% - two steps). ^{13}C -NMR δ 20.0(q), 26.2(q), 27.2(t), 28.9(t), 32.0(t), 46.2(d), 67.0(s), 105.3(s), 127.0(d), 128.3(d), 130.0(d), 145.2(s), 165.6(s).

2,2-Dimethyl-4,6-dioxo-5-[3-[(triphenylmethyl)thio]propyl]-1,3-dioxane-5-propanoic acid methylester (II)

5 mmol of 2,2-dimethyl-5-[3-[(triphenylmethyl)-thio]propyl]-1,3-dioxane-5-propanoic-4,6-dione (I) (2.3 g), was dissolved with 20 mmol methyl-3-bromopropionate (3.34g = 2.18 ml) and 4.6 ml of 4.37 M methanolic solution of sodium methoxide (20 mmol) in 10 ml of methanol. The reaction mixture was heated to 60° C overnight after which TLC in hexane/ethylacetate 1:1 detected no starting material. The mixture was then evaporated to dryness and mixed with 40 ml of aqueous 10% KHSO_4 . The organic material was extracted by 3 portions of EtOAc, the organic layers were combined dried with MgSO_4 and evaporated. The residue was crystallized from hexane/ethylacetate to yield 2.1 g (77%) of 2,2-dimethyl-4,6-dioxo-5-[3-[(triphenylmethyl)thio]propyl]-1,3-dioxane-5-propanoic acid

WO 01/01974

PCT/US00/18260

92

methyl ester (II), ^{13}C -NMR (CDCl_3) δ 24.6, 29.4, 29.5, 29.6, 31.4, 32.6, 37.7, 51.9, 52.8, 66.8, 105.7, 126.7, 127.9, 129.5, 144.7, 168.4, 172.0.

5 **6-[(triphenylmethyl)thio]-1,3,3-hexanetricarboxylic acid (III)**

2.56 mmol of 2,2-dimethyl-4,6-dioxo-5-[3-[(triphenylmethyl)thio]propyl]-1,3-dioxane-5-propanoic acid methyl ester (II) (1.4 g) with 18 mmol of sodium hydroxide (0.72 g) was dissolved in a mixture of 5 ml of 1,4-dioxane and 5 ml of water. The mixture was then heated to 100° C for 1 hour, evaporated to dryness, dissolved in water and precipitated by addition of 1 M sulfuric acid. The precipitate was filtered off, washed with water and dried in a dessicator. Yield 1.36 g of 6-[(triphenylmethyl)thio]-1,3,3-hexanetricarboxylic acid (III) (-100%), ^{13}C -NMR (MeOH) δ 25.4, 29.2, 30.7, 33.5, 33.7, 58.0, 68.3, 128.1, 129.3, 131.2, 146.7, 174.9, 176.9.

20

6-[(triphenylmethyl)thio]-1,3-hexanedicarboxylic acid (IV)

2.56 mmol of 6-[(triphenylmethyl)thio]-1,3,3-hexanetricarboxylic acid (III) (1.36 g) was dissolved in 5 ml of dimethylsulfoxide and the solution was heated to 100° C for 1 hour, evaporated to dryness, dissolved in water and precipitated by addition of 1 M sulfuric acid. The precipitated oil solidified

25

WO 01/01974

PCT/US00/18260

93

after 1 hour treatment in an ultrasound bath. The solid was filtered off, washed with water and dried in a dessicator. Yield 1.1 g of 6-[(triphenylmethyl)-thio]-1,3-hexanedicarboxylic acid (IV) (89% two steps from II), ^{13}C -NMR (MeOH) δ 27.9, 28.6, 33.0 (two carbons), 33.1, 45.9, 68.1, 128.1, 129.2, 131.2, 146.8, 177.1, 179.4.

10 **2-(3-sulfanylpropyl)pentanedioic acid (V)**

2.46 mmol of 6-[(triphenylmethyl)thio]-1,3-hexanedicarboxylic acid (IV) (1.1 g) with 5 mmol triisopropylsilane (0.79 g) was dissolved in a mixture of 3 ml CH_2Cl_2 /3 ml trifluoroacetic acid and left to stand at room temperature for 1 hour. The mixture was then evaporated to dryness and washed 3x with hexane. The remaining oily residue was dissolved in water, filtered and lyophilized to yield 0.35 g of 2-(3-sulfanylpropyl)pentanedioic acid (V) (76%), ^{13}C -NMR (MeOH) δ 25.2(t), 28.8(t), 32.4(t), 33.0(t), 33.2(t), 45.9(d), 177.2(s), 179.6(s).

EXAMPLE 12

Preparation of 2-(4-sulfanylbutyl)pentanedioic acid

25 2-(4-sulfanylbutyl)pentanedioic acid was prepared using the methods described above for 2-(3-sulfanylpropyl)pentanedioic acid.

^{13}C -NMR (MeOH) δ 25.1(t), 27.4(t), 28.8(t), 33.0(t),

WO 01/01974

PCT/US00/18260

94

33.2(t), 35.4(t), 46.3(d), 177.2(s), 179.7(s).

EXAMPLE 13**Preparation of 2-(3-sulfanyl-2-methylpropyl)-****5 pentanedioic acid**

2-(3-sulfanyl-2-methylpropyl)pentanedioic acid (mixture of two diastereoisomers) was prepared using the methods described above for 2-(3-sulfanylpropyl)-pentanedioic acid.

10 ¹³C-NMR (MeOH) δ 18.9(q), 19.5(q), 29.1(t), 29.6(t), 31.7(t), 32.6(t), 32.9(t), 33.0(t), 35.5(d), 35.9(d), 39.2(t), 39.7(t), 44.2(d), 44.3(d), 177.0(s), 177.1(s), 179.7(s), 179.9(s).

15 EXAMPLE 14**Anxiolytic Activity**

Compounds 1, 2 and 3 (identified under "DEFINITIONS") were tested in an anxiolytic model termed "passive avoidance". Compounds 1, 2 and 3 were
20 found to exhibit anxiolytic properties. In fact, in some experiments they performed better than the known anxiolytic agent, flurazepam. The results of this study are set forth in TABLES I and II of the APPENDIX.

25 The passive avoidance test consists of an acquisition and a retention trial. On the day prior to dosing, the animal is placed into the shuttlebox and allowed to acclimate. A conditioned stimulus

WO 01/01974

PCT/US00/18260

95

(light) is presented for approximately 100 seconds. When the animal crosses to the dark compartment, a mild (0.5 mA) footshock is presented until the animal returns to the lighted compartment or for approximately 10 seconds. Animals failing to cross during acquisition trial is randomly replaced. The day following acquisition, animals are administered test article, saline or flurazepam 10 minutes prior to being placed in the shuttlebox and tested for retention as described above. Latency to cross (in seconds) is recorded.

EXAMPLE 15

Anxiolytic Activity

2-(2-sulfanylpropyl)pentanedioic acid and 2-(3-sulfanylpropyl)pentanedioic acid are tested in the passive avoidance anxiolytic model. Each of the compounds is found to exhibit anxiolytic properties.

EXAMPLE 16

Memory Enhancing Activity

The effects of NAALADase inhibitors on memory enhancement are tested on a T16 maze model. The T16 maze model is described in detail elsewhere (see, for example, Shimada et al., *European Journal of Pharmacology*, Vol. 263, pp. 293-300 (1994); Spangler, *Physiology & Behavior*, Vol. 56, No. 1, pp. 95-101 (1994)).

WO 01/01974

PCT/US00/18260

96

Pretraining is conducted in a 2-meter long straight runway, constructed of clear Plexiglass. The floor is constructed of stainless steel grids wired to distribute a constant-current scrambled shock. A hand-held switch initiates a foot-shock and starts a clock that recorded the time to traverse the runway. Interchangeable black Plexiglas start and goal boxes can be placed over the grid floors at either end of the runway. On the day of pretraining, the rat is placed in one of the black boxes, the box is inserted into the start position of the runway, and a timer is initiated. The rat is pushed gently into the runway and is allowed 10 seconds to enter the goalbox to avoid a footshock (0.8 mA). Upon entry to the goal box, a guillotine door is lowered, the goal box is returned to the start area (after a 90 second ITI), and the next trial is initiated. Each rat continues to receive massed training trials until a criterion of 13/15 avoidances is met (max = 30 trials).

Acquisition training is conducted in a clear Plexiglas 14-unit T-maze. The maze is separated into five distinct sections by guillotine doors that prevent animals from backtracking into previous sections. Nonfunctional guillotine doors at the entry to each cul-de-sac prevent the functional doors from being used as cues to the correct pathway. A switchbox triggers a clock which, when timed out, activates a counter that record the number of shocks

WO 01/01974

PCT/US00/18260

97

(max = 5/trial). Infrared photocells throughout the maze record the number of errors (defined as any deviation from the correct pathway) and runtime. The maze is surrounded by painted gray wooden walls to reduce extra-maze visual cues. Speakers are located under the maze at each corner and provide music to reduce auditory cues. The maze can be hoisted by motor driven pulleys to clean the grid floor and reduce the presence of odor cues.

For acquisition training, 24 hours after pretraining, the rat is placed into a start box and the box is inserted into the start position. The rat is pushed gently into the maze, the door is closed, and the clock controlling the shock contingency is initiated. In each section of the maze, the rat is given 10 seconds to escape through the door to the next section. After 10 seconds, a footshock is delivered until the rat escapes through the door. When the rat passes into the next section, the door is lowered behind the animal, and the clock contingency is reset. Upon entering the goal box, the door is closed, the box is placed in a holding area for 90 seconds, and the maze is hoisted for cleaning. Each rat receives a total of 15 massed trials with a 2 minute intertrial interview.

Rats are randomly assigned to treatment groups. Saline and NAALADase inhibitors, including Compounds 1, 2 and 3, 2-(2-sulfanylpentyl)-pentanedioic acid and

WO 01/01974

PCT/US00/18260

98

2- (3-sulfanylpropyl)pentanedioic acid are administered
by intraperitoneal injection approximately 30 minutes
prior to initiation of testing. Doses are chosen to
be within the therapeutically effective range for each
5 compound.

Rats treated with a therapeutically effective
amount of a NAALADase inhibitor perform better than
control rats treated with saline. The results
demonstrate that NAALADase inhibitors enhance memory
10 in mammals.

WO 01/01974

PCT/US00/18260

99

All publications, patents and patent applications identified above are herein incorporated by reference.

The invention being thus described, it will be obvious that the same may be varied in many ways.

5 Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.


WO 01/01974

PCT/US00/18260

100

WE CLAIM:

1. A method for treating a glutamate mediated disease, disorder or condition selected from the group consisting of anxiety, anxiety disorder and memory impairment, comprising administering an effective amount of a NAALADase inhibitor to a mammal in need of such treatment.
2. The method of claim 1, wherein the NAALADase inhibitor is an acid containing metal chelator.
3. The method of claim 1, wherein the NAALADase inhibitor is a compound of formula I:



- 20 or a pharmaceutically acceptable equivalent, wherein:

Y is CR₃R₄, NR₅ or O;

- R₁ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, Ar, COOR, NR₆R₇ and OR, wherein said alkyl, alkenyl, cycloalkyl and cycloalkenyl are unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇
- 25

WO 01/01974

PCT/US00/18260

101

cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, phenoxy, benzyloxy, COOR, NR₆R₇ and Ar;

R₂ is selected from the group consisting of
5 hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, Ar, halo and carboxy, wherein said alkyl, alkenyl, cycloalkyl and cycloalkenyl are unsubstituted or substituted with one or more substituent(s) independently selected from the group
10 consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, phenoxy, benzyloxy, NR₆R₇ and Ar;

R₃ and R₄ are independently hydrogen or C₁-C₃
15 alkyl;

R₅ is hydrogen or C₁-C₃ alkyl;

R, R₆ and R₇ are independently selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl and Ar,
20 wherein said alkyl, alkenyl, cycloalkyl and cycloalkenyl are unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, phenoxy, benzyloxy and Ar; and
25

Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 4-indolyl,

WO 01/01974

PCT/US00/18260

102

2-furyl, 3-furyl, tetrahydrofuranyl, tetrahydropyranyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, wherein said Ar is unsubstituted or substituted with one or more
5 substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, phenoxy, benzyloxy, carboxy and NR₁R₂.

10 4. The method of claim 3, wherein Y is CH₂.

5. The method of claim 4, wherein R₂ is - (CH₂)₂COOH.

15 6. The method of claim 5, wherein R₁ is hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, benzyl, phenyl or OR, wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, benzyl and phenyl are unsubstituted or substituted with one or
20 more substituent(s) independently selected from the group consisting of carboxy, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, phenoxy, benzyloxy, NR₆R₇, benzyl and
25 phenyl.

7. The method of claim 6, wherein the compound of formula I is selected from the group consisting of:

WO 01/01974

PCT/US00/18260

103

- 2-(phosphonomethyl)pentanedioic acid;
- 2-[[(2-carboxyethyl)hydroxyphosphinyl]methyl] -
pentanedioic acid;
- 2-[(benzylhydroxyphosphinyl)methyl]pentanedioic
5 acid;
- 2-[(phenylhydroxyphosphinyl)methyl]pentanedioic
acid;
- 2-[[((hydroxy)phenylmethyl)hydroxyphosphinyl] -
methyl]pentanedioic acid;
- 10 2-[(butylhydroxyphosphinyl)methyl]pentanedioic
acid;
- 2-[[(3-methylbenzyl)hydroxyphosphinyl]methyl] -
pentanedioic acid;
- 2-[(3-phenylpropylhydroxyphosphinyl)methyl] -
15 pentanedioic acid;
- 2-[[(4-fluorophenyl)hydroxyphosphinyl]methyl] -
pentanedioic acid;
- 2-[(methylhydroxyphosphinyl)methyl]pentanedioic
acid;
- 20 2-[(phenylethylhydroxyphosphinyl)methyl] -
pentanedioic acid;
- 2-[[(4-methylbenzyl)hydroxyphosphinyl]methyl] -
pentanedioic acid;
- 2-[[(4-fluorobenzyl)hydroxyphosphinyl]methyl] -
25 pentanedioic acid;
- 2-[[(4-methoxybenzyl)hydroxyphosphinyl]methyl] -
pentanedioic acid;
- 2-[[(3-trifluoromethylbenzyl)hydroxyphosphinyl] -

WO 01/01974

PCT/US00/18260

104

methyl]pentanedioic acid;

2-[[4-trifluoromethylbenzyl)hydroxyphosphinyl]-
methyl]pentanedioic acid;

2-[[[(2-fluorobenzyl)hydroxyphosphinyl)methyl]-
5 pentanedioic acid;


2-[[[(2,3,4,5,6-pentafluorobenzyl)hydroxy-
phosphinyl)methyl]pentanedioic acid; and

pharmaceutically acceptable equivalents.

10 8. The method of claim 7, wherein the compound
of formula I is 2-[[[(2,3,4,5,6-pentafluorobenzyl)-
hydroxyphosphinyl)methyl]pentanedioic acid or a
pharmaceutically equivalent.

15 9. The method of claim 8, wherein the compound
of formula I is an enantiomer or an enantiomer-
enriched mixture.

20 10. The method of claim 1, wherein the NAALADase
inhibitor is a compound of formula II



25


or a pharmaceutically acceptable equivalent, wherein:

X is a moiety of formula III, IV or V

WO 01/01974


PCT/US00/18260

105




5

III



IV



10

V;

m and n are independently 0, 1, 2, 3 or 4;

Z is SR_{13} , SO_3R_{13} , SO_2R_{13} , SOR_{13} , $\text{SO}(\text{NR}_{13})\text{R}_{14}$ or

15 $\text{S}(\text{NR}_{13}\text{R}_{14})_2\text{R}_{15}$;

B is N or CR_{16} ;

A is O, S, $\text{CR}_{17}\text{R}_{18}$ or $(\text{CR}_{17}\text{R}_{18})_m\text{S}$;

R_9 and R_{13} are hydrogen;

20 R_8 , R_{10} , R_{11} , R_{12} , R_{14} , R_{15} , R_{16} , R_{17} and R_{18} are independently hydrogen, $\text{C}_1\text{-C}_9$ straight or branched chain alkyl, $\text{C}_2\text{-C}_9$ straight or branched chain alkenyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_5\text{-C}_7$ cycloalkenyl, Ar_1 , hydroxy, carboxy, carbonyl, amino, amido, cyano, isocyano, nitro, sulfonyl, sulfoxy, thio, thiocarbonyl, 25 thiocyano, formamido, thioformamido, sulfhydryl, halo, haloalkyl, trifluoromethyl or oxy, wherein said alkyl, alkenyl, cycloalkyl and cycloalkenyl are independently unsubstituted or substituted with one or

WO 01/01974

PCT/US00/18260

106

more substituent(s); and


Ar_1 is a carbocyclic or heterocyclic moiety, which is unsubstituted or substituted with one or more substituent(s);

5 provided that when X is a moiety of formula III and A is O, then n is 2, 3 or 4; when X is a moiety of formula III and A is S, then n is 2, 3 or 4; and when X is a moiety of formula III and A is $(CR_{17}R_{18})_mS$, then n is 0, 2, 3 or 4.

10

11. The method of claim 10, wherein the NAALADase inhibitor is a compound of formula VI

15



VI

or a pharmaceutically acceptable equivalent, wherein:

20

n is 0, 1, 2 or 3;

Z is SH, SO_3R_{13} , SO_2R_{13} , SOR_{13} or $S(NR_{13}R_{14})_2R_{15}$; and

A is O, S or $CR_{17}R_{18}$.

25

12. The method of claim 11, wherein Z is SH.

13. The method of claim 12, wherein R_8 is $-(CH_2)_2COOH$.

WO 01/01974

PCT/US00/18260

107

14. The method of claim 12, wherein the compound of formula VI is selected from the group consisting of:

- 2-(2-sulfanylethyl)pentanedioic acid;
- 5 3-(2-sulfanylethyl)-1,3,5-pentanetricarboxylic acid;
- 2-(2-sulfanylpropyl)pentanedioic acid;
- 2-(2-sulfanylbutyl)pentanedioic acid;
- 2-(2-sulfanyl-2-phenylethyl)pentanedioic acid;
- 10 2-(2-sulfanylhexyl)pentanedioic acid;
- 2-(2-sulfanyl-1-methylethyl)pentanedioic acid;
- 2-[1-(sulfanylmethyl)propyl]pentanedioic acid;
- 2-(3-sulfanylpentyl)pentanedioic acid;
- 2-(3-sulfanylpropyl)pentanedioic acid;
- 15 2-(3-sulfanyl-2-methylpropyl)pentanedioic acid;
- 2-(3-sulfanyl-2-phenylpropyl)pentanedioic acid;
- 2-(3-sulfanylbutyl)pentanedioic acid;
- 2-[3-sulfanyl-2-(phenylmethyl)propyl]pentanedioic acid;
- 20 2-[2-(sulfanylmethyl)butyl]pentanedioic acid;
- 2-[2-(sulfanylmethyl)pentyl]pentanedioic acid;
- 2-(3-sulfanyl-4-methylpentyl)pentanedioic acid;
- and
- pharmaceutically acceptable equivalents.

25

15. The method of claim 14, wherein the compound of formula VI is selected from the group consisting of 2-(2-sulfanylethyl)pentanedioic acid, 2-(2-

WO 01/01974

PCT/US00/18260

108

sulfanylpropyl)pentanedioic acid, 2-(3-sulfanylpropyl)pentanedioic acid and pharmaceutically acceptable equivalents.

5 16. The method of claim 15, wherein the compound of formula VI is an enantiomer or an enantiomer-enriched mixture.

10 17. The method of claim 1, wherein the NAALADase inhibitor is administered in combination with at least one additional therapeutic agent.

15 18. The method of claim 1, wherein the glutamate mediated disease, disorder or condition is an anxiety disorder selected from the group consisting of panic attack, agoraphobia, panic disorder, acute stress disorder, chronic stress disorder, specific phobia, simple phobia, social phobia, substance induced anxiety disorder, organic anxiety disorder, obsessive compulsive disorder, post-traumatic stress disorder, 20 generalized anxiety disorder, and anxiety disorder NOS.

25 19. The method of claim 1, wherein the glutamate mediated disease, disorder or condition is memory impairment.

20. A pharmaceutical composition comprising:

WO 01/01974

PCT/US00/18260

109

- 5 (i) an effective amount of a NAALADase inhibitor
for treating a glutamate mediated disease,
disorder or condition selected from the
group consisting of anxiety, anxiety
disorder and memory impairment; and
(ii) a pharmaceutically acceptable carrier.

WO 01/01974

PCT/US00/18260

1

APPENDIX

TABLE I

Passive Avoidance-Individual Animals

Treatment Animal #		Latency to Cross (seconds)	
		Acquisition Trial	Retention Trial
Saline	16	9.7	73.2
0 mg/kg;	2	9.0	16.1
IP	3	4.1	2.9
	4	3.3	1.5
	5	0.2	8.9
	6	1.3	27.9
	7	4.9	11.0
	8	16.4	5.3
	9	6.9	27.4
	10	14.2	100.0
	11	16.8	2.5
	12	12.5	100.0
	13	1.2	21.3
	14	2.1	7.0
	15	5.2	7.6
	MEAN	7.2	27.5
	SD	5.6	34.4

WO 01/01974

2

PCT/US00/18260

TABLE I (continued)
Passive Avoidance-Individual Animals

Treatment Animal #		Latency to Cross (seconds)	
		Acquisition	Retention
		Trial	Trial
Flurazepam	1	7.0	83.3
3 mg/kg;	17	9.5	100.0
IP	18	8.8	100.0
	19	2.8	5.5
	20	19.3	100.0
	21	5.4	4.7
	22	8.2	100.0
	23	28.2	16.1
	24	7.1	65.3
	25	2.4	6.9
	26	16.7	2.1
	27	8.4	34.1
	28	11.3	2.2
	29	6.9	47.5
	30	9.1	34.9
	MEAN	10.1	47.5
	SD	6.7	40.1

WO 01/01974

3

PCT/US00/18260

TABLE I (continued)
Passive Avoidance-Individual Animals

Treatment Animal #		Latency to Cross (seconds)	
		Acquisition Trial	Retention Trial
Compound 2	31	4.0	9.8
100 mg/kg;	32	0.1	7.1
IP	33	14.9	4.8
	34	5.0	100.0
	35	6.4	100.0
	36	9.5	88.4
	37	4.6	7.8
	38	5.7	15.8
	39	0.1	100.0
	40	13.0	100.0
	41	5.1	100.0
	42	6.2	100.0
	43	10.1	68.4
	44	4.3	100.0
	45	11.4	100.0
	MEAN	6.7	66.8 ^a
	SD	4.3	43.1

^aIndicates significance difference compared to Group 1; $p \leq 0.05$.

WO 01/01974

4

PCT/US00/18260

TABLE I (continued)
Passive Avoidance-Individual Animals

Treatment	Animal #	Latency to Cross (seconds)	
		Acquisition Trial	Retention Trial
Saline	104	10.3	14.9
0 mg/kg;	107	13.1	1.0
IP	110	1.8	17.5
	113	8.8	11.8
	115	0.3	12.0
	201	2.7	13.4
	204	1.0	0.4
	206	12.0	6.4
	214	2.5	16.1
	215	0.6	2.1
	305	9.5	17.5
	401	6.8	49.2
	402	11.6	18.7
	411	5.5	3.1
	413	43.6	21.1
	MEAN	8.7	13.7
	SD	10.7	12.0

WO 01/01974

5

PCT/US00/18260

TABLE I (continued)
Passive Avoidance-Individual Animals

Treatment Animal #		Latency to Cross (seconds)	
		Acquisition Trial	Retention Trial
Flurazepam	101	6.6	11.2
5 mg/kg;	102	39.8	56.3
IP	108	2.7	10.5
	109	10.6	23.9
	111	0.5	6.5
	112	0.1	6.0
	203	7.4	13.4
	207	4.0	0.8
	208	4.9	21.4
	212	14.7	2.9
	306	10.1	67.2
	307	9.5	19.0
	310	1.9	58.3
	404	12.9	4.8
	407	0.7	9.7
	MEAN	8.4	20.8
	SD	9.8	21.7

WO 01/01974

6

PCT/US00/18260

TABLE I (continued)
Passive Avoidance-Individual Animals

Treatment Animal #		Latency to Cross (seconds)	
		Acquisition	Retention
		Trial	Trial
Compound 3 100 mg/kg; IP	105	9.3	6.6
	202	0.2	33.0
	205	2.0	89.8
	308	5.9	100.0
	309	6.1	5.2
	312	25.0	5.9
	313	2.2	100.0
	314	10.5	8.5
	403	11.8	100.0
	405	11.5	100.0
	408	9.2	4.6
	409	0.8	9.9
	410	0.6	47.4
	412	2.9	12.9
	415	18.6	20.6
	MEAN	7.8	43.0
	SD	7.1	41.9

WO 01/01974

7

PCT/US00/18260

TABLE I (continued)
Passive Avoidance-Individual Animals

Treatment Animal #		Latency to Cross (seconds)	
		Acquisition Trial	Retention Trial
Compound 2	103	0.0	3.1
100 mg/kg;	106	11.4	33.9
IP	114	12.1	100.0
	209	1.5	13.2
	210	1.6	6.6
	211	7.0	39.4
	213	6.8	7.9
	301	20.0	33.2
	302	2.3	100.0
	303	0.6	8.4
	304	9.6	41.5
	311	3.2	19.5
	315	10.4	7.3
	406	5.7	100.0 ^b
	414	18.7	0.3
	MEAN	7.5	29.6
	SD	6.5	32.9

^bOmitted from statistical analysis; animal showing clinical signs prior to dosing.

WO 01/01974

8

PCT/US00/18260

TABLE II
Passive Avoidance-Individual Animals

Treatment	Animal #	Latency to Cross (seconds)
Control PO	216	17.9
	217	100.0
	218	2.3
	219	5.8
	220	100.0
	221	11.8
	222	17.2
	223	45.7
	224	26.9
	225	75.3
	226	10.3
	227	100.0
	228	8.7
	229	40.3
	230	100.0
	Mean	44.1
	SEM	10.2

WO 01/01974

9

PCT/US00/18260

TABLE II (continued)
Passive Avoidance-Individual Animals

Treatment	Animal #	Latency to Cross (seconds)
Flurazepam, 5 mg/kg IP	103	4.7
	104	9.6
	105	4.1
	106	26.0
	107	0.3
	108	4.0
	109	8.0
	110	3.5
	111	12.0
	112	4.0
	113	16.9
	114	89.0
	115	6.4
	131	4.1
	132	0.3
	Mean	12.9
	SEM	5.7

WO 01/01974

10

PCT/US00/18260

TABLE II (continued)
Passive Avoidance-Individual Animals

Treatment	Animal #	Latency to Cross (seconds)
Compound 1 1 mg/kg PO	316	5.9
	317	15.8
	318	28.4
	319	30.3
	320	100.0
	321	12.3
	322	27.9
	323	23.5
	324	3.9
	325	13.1
	326	100.0
	327	0.2
	328	41.3
	329	100.0
	330	20.1
Mean		34.8
SEM		9.1

WO 01/01974

11

PCT/US00/18260

TABLE II (continued)

Passive Avoidance-Individual Animals

Treatment	Animal #	Latency to Cross (seconds)
Compound 1 10 mg/kg PO	416	1.8
	417	28.5
	418	64.1
	419	3.2
	420	14.7
	421	10.3
	422	3.3
	423	24.6
	424	9.4
	425	100.0
	426	22.7
	427	6.6
	428	14.0
	429	38.8
	430	12.1
	Mean	23.6
	SEM	6.9

WO 01/01974

12

PCT/US00/18260

TABLE II (continued)
Passive Avoidance-Individual Animals

Treatment	Animal #	Latency to Cross (seconds)
Compound 1 100 mg/kg PO	516	15.0
	517	19.2
	518	5.6
	519	19.3
	520	6.2
	521	55.7
	522	25.5
	523	21.5
	524	6.6
	525	15.1
	526	8.4
	527	17.4
	528	0.5
	529	0.7
	530	52.8
Mean		18.0
SEM		4.3

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.